0001387131-19-002745.txt : 20190418 0001387131-19-002745.hdr.sgml : 20190418 20190418144245 ACCESSION NUMBER: 0001387131-19-002745 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20160831 FILED AS OF DATE: 20190418 DATE AS OF CHANGE: 20190418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phoenix Life Sciences International Limited. CENTRAL INDEX KEY: 0001493212 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 460525378 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-167275 FILM NUMBER: 19755594 BUSINESS ADDRESS: STREET 1: 3000 LAWRENCE STREET CITY: DENVER STATE: CO ZIP: 80205 BUSINESS PHONE: 1.720.699.7222 MAIL ADDRESS: STREET 1: 3000 LAWRENCE STREET CITY: DENVER STATE: CO ZIP: 80205 FORMER COMPANY: FORMER CONFORMED NAME: MEDIJANE HOLDINGS INC. DATE OF NAME CHANGE: 20140310 FORMER COMPANY: FORMER CONFORMED NAME: MOKITA, INC. DATE OF NAME CHANGE: 20130604 FORMER COMPANY: FORMER CONFORMED NAME: MOKITA VENTURES, INC. DATE OF NAME CHANGE: 20120521 10-Q 1 plsi-10q_083116.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended August 31, 2016

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period From to

Commission File Number: 333-167275

Phoenix Life Sciences International Limited

(Exact name of registrant as specified in its charter)

Nevada		46-0525378
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3000 Lawrence Street, Denver, CO		80205
(Address of principal executive offices)		(Zip Code)

(720) 699.7222

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company)		Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding as of February 28, 2019
Common Stock, $0.001 par value per share		32,584,582 shares

Phoenix Life Sciences International Limited

FORM 10-Q

For the Quarter Ended August 31, 2016

INDEX

			Page
PART I.	FINANCIAL INFORMATION
	Item 1.	Financial Statements (unaudited)	3
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
	Item 4.	Controls and Procedures	26

PART II.	OTHER INFORMATION
	Item 1.	Legal Proceedings	26
	Item 1A.	Risk Factors	27
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
	Item 3.	Defaults upon Senior Securities	27
	Item 4.	Mine Safety Disclosures	27
	Item 5.	Other Information	27
	Item 6.	Exhibits	27

SIGNATURE			28

Forward Looking Statements.

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors”, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in United States Dollars ($) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States Dollars and all references to “common shares” refer to the common shares in our capital stock.

Except as otherwise indicated by the context, references in this report to “we”, “us” “our” and “the Company” are references to Phoenix Life Sciences International Limited.

Item 1. Financial Statements

Phoenix Life Sciences International Limited

Consolidated Balance Sheets


	August 31, 2016 $			February 29, 2016 $
	Unaudited			Audited
ASSETS

Cash		2,519			7,591
Notes receivable, related party		238,252			249,352
Total Current Assets		240,771			256,943
Total Assets		240,771			256,943

LIABILITIES

Current Liabilities
Accounts payable and accrued liabilities		500,053			512,642
Due to related parties		267,219			267,219
Current Liabilities		767,272			779,861

Convertible notes payable, net		297,708			193,306
Derivative liability		243,579			397,512
Total Liabilities		1,308,559			1,370,679

STOCKHOLDERS’ DEFICIT

Common Stock
Authorized: 990,000,000 common shares, par value of $0.001 per share
Issued and outstanding: 28,245 and 25,845 common shares, respectively		28			26
Issued and outstanding Preferred shares Series B – 2,000,000		200			200
Series C – 995,600 and 998,000 respectively		100			100

Additional paid-in capital		17,704,975			17,704,977

Accumulated deficit during the development stage		(18,773,091	)		(18,819,039	)
Total Stockholders’ Equity (Deficit)		(1,067,788	)		(1,113,736	)
Total Liabilities and Stockholders’ Equity		240,771			256,943

(The accompanying notes are an integral part of these financial statements)

Phoenix Life Sciences International Limited

Consolidated Statements of Operations - Unaudited

	Three Months Ended						Six Months Ended
	August 31, 2016			August 31, 2015			August 31, 2016			August 31, 2015
Income Statement				restated						restated
Revenues	$	—		$	15,975		$	—		$	18,410
Cost of Sales		—			5,035			—			5,933
Gross Profit		—			10,940			—			12,477

Operating expenses
Product development expense		—			70,000			—			100,000
Sales and marketing expenses		—			6,306			—			14,345
Operations expense		—			—			—			1,745
General and administrative		1,273			15,080			3,253			30,876
Professional fees					79,437			330			217,712
Lease operating expenses		—			—			—			7,500
Total operating expenses		1,273			170,823			3,583			372,178
Loss before other expenses		(1,273	)		(159,883	)		(3,583	)		(359,701	)

Other income (expense)
Interest Income		—			980			—			2,093
Interest Expense		(16,271	)		(41,024	)		(101,967	)		(86,140	)
Debt Issue costs		—			(7,830	)		—			(7,830	)
Discount Amortization		—			—			(2,435	)		(46,049	)
Gain (loss) on derivative liability		178,576			28,022			153,933			94,537
Total other income (expense)		162,305			(19,852	)		49,531			(43,389	)
Net profit (loss)		161,031			(179,735	)		45,948			(403,090	)

Basic and diluted loss per common share:
Income (loss) from continuing operations		5.70			(0.00	)		1.63			(0.00	)
Basic and diluted loss per common share	$	5.70		$	0		$	1.63		$	(0.00	)
Weighted average shares outstanding - basic and diluted		28,245			258,030,222			28,206			364,290,048

(The accompanying notes are an integral part of these financial statements)

Phoenix Life Sciences International Limited

Consolidated Statements of Cash Flows

(Unaudited)

		Six Months Ended
		August 31, 2016			August 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss	$		45,948		$	(403,090	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash amortization of discount on convertible notes payable			2,435			46,049
Non-cash interest expense on convertible notes payable			101,967			86,140
Non-cash stock option compensation			—			—
Non-cash loss (gain) on derivative liability			(153,933	)		(94,537	)

Changes in operating assets and liabilities:
Accounts receivable			—			2,300
Deposit						1,250
Inventory			—			5,933
Accounts payable and accruals			(12,589	)		226,871
Net Cash provided by (used for) operating activities			(16,172	)		(129,084	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Related party notes receivable			11,100			8,907
Net Cash provided by (used in) Investing Activities			11,100			8,907

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from notes payable						—
Due to related parties			—			111,250
Net Cash Provided By Financing Activities			—			111,250
Increase (Decrease) in Cash - continuing operations			(5,072	)		(8,927	)
Cash - Beginning of Period - continuing operations			7,591			9,400
Cash - End of Period - continuing operations	$		2,519		$	473

Supplemental disclosures
Interest paid	—	—
Income tax paid	12,589	—
Non-cash issuance of stock for consulting agreements	—	—
Non-cash issuance of stock for distribution agreement	—	—
Non-cash issuance of stock for conversion of debt	—	29,000

(The accompanying notes are an integral part of these financial statements)

Nature of Operations and Continuance of Business

The company was incorporated in the State of Nevada on April 21, 2009 under the name Mokita Exploration, Ltd. (the “Company”). On February 27, 2014, there was a change of control of the Company. On February 28, 2014, our board of directors and a majority of holders of the Company’s voting securities approved a change of name of the Company to MediJane Holdings Inc. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on March 4, 2014. A Certificate of Correction was subsequently filed with the Nevada Secretary of State on March 6, 2014 to correct a spelling error in the Company’s new name. These amendments have been reviewed by FINRA and were approved for filing with an effective date of March 12, 2014. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on March 12, 2014 under our new ticker symbol “MJMD”.

On March 8, 2017 the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company changed its name with the State of Nevada from MediJane Holdings, Inc. to Stem Bioscience, Inc.

In May 2018 the Company again changed its name to Phoenix Life Sciences International Limited. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on May 31, 2018. The name change was accepted by FINRA and became effective with the Over-the- Counter Bulletin Board on November 2, 2018 with the trading symbol “PLSI”.

On February 27, 2014, after the change of control, the Company became a sales and distribution company focused on cannabinoid infused products for the treatment of medical conditions.

On January 5, 2015, the Company underwent a change in control following the issuance of 276,000,000 common shares to Phoenix Bio Pharmaceuticals Corporation pursuant to a license agreement. On November 4, 2015, these shares were exchanged for 2,000,000 Series B Preferred Shares.

The business was then changed to only focus on Cannabidiol (CBD) products. CBD is a non-psychotropic cannabinoid that is not restricted as part of the U.S. Controlled Substances Act (CSA), as defined under the 2014 U.S Farming Bill to be derivatives of the Industrial Hemp plant that contains less than 0.3% tetrahydrocannabinol (THC). The company will contract out the manufacturing of the products. Phoenix Bio Pharmaceuticals Corporation and other groups may manufacture our products under our license agreement.

The Company follows the accounting guidance outlines in the Financial Accounting Standards Board Codification guidelines. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted principles for interim financial information and with the items under Regulation S-K required by the instructions to Form 10-Q. They may not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed here in, there have been no material change in the information disclosed in the notes to the financial statements for the year ended February 29, 2016 included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2019. The interim unaudited financial statements presented herein should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, which unless otherwise disclosed herein, consistent with normal re-occurring adjustments, have been made. Operating results for three months ended August 31, 2016 are not necessarily indicative results that may be expected for the year ended February 28, 2017.

Going Concern

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company’s total operating expenditure plan for the following twelve months will require significant cash resources to meet the goals of its business plan. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies

Basis of Presentation – The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28 or 29.

Basis of Consolidation – The consolidated financial statements include the accounts of Phoenix Life Sciences International Limited and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

On March 17, 2014, MediHoldings, Inc (“MediHoldings”), a Colorado corporation, was formed as a wholly owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly owned subsidiary of the Company. These companies have not traded and are inactive.

Stock Split – on October 21, 2015 the Company’s Board of Directors declared a One for 10,000 reverse stock split on its common stock as of a record date of October 22, 2015. The effect of the stock split decreased the number of shares of common stock outstanding from 501,242,594 to 50,125. All common share and per common share data in these financial statements and related notes here to have been retroactively adjusted to account for the effect of the stock split for all periods presented. The total number of authorized common shares on the par value thereof was not changed by the split.

Use of Estimates – The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

A significant item that requires management’s estimates and assumptions is the valuation of intangible assets, valuation allowances for income tax, valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.

Cash and cash equivalents – The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. At August 31, 2016 and February 28, 2016, the Company did not hold any cash equivalents.

Accounts receivable – Accounts receivable consists of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts receivable are carried at the original invoice amount less a reserve for doubtful receivables based on a review of all outstanding amounts on a monthly basis.

Basic and Diluted Net Loss per Share – The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. At February 28, 2016 and August 31, 2016, the Company had no outstanding stock options. At August 31, 2016 and 2015, the Company had did not have potentially dilutive shares outstanding.

Financial Instruments – Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 – Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 – Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 – Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

Derivative Financial Instruments – The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks.

The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.

The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.

Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.

Comprehensive Loss – ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at August 31, 2016 and 2015, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

Stock-based Compensation – The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Based Compensation and ASC 505-50 - Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

We account for share-based payments granted to non-employees in accordance with ASC Topic 505, “Equity Based Payments to Non-Employees.” The Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.

The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:

Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.

Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.

Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.

Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant.

Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

Revenue Recognition – The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin Topic 13 when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection is probable. The Company assesses whether the fee is fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. Up-front engagement fees are recorded as deferred revenue and amortized to income on a straight-line basis over the term of the agreement, although the fee is due and payable at the time the agreement is signed or upon annual renewal. Payments related to substantive, performance-based milestones in an agreement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreement when they represent the culmination of the earnings process.

The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a fee is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates.

Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations.

Recent Accounting Pronouncements – The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Reclassifications - Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

Variable Interest Entity

The Company follows the guidelines in FASB Codification of ASC 810 “Consolidation” which indicates “a legal entity that is deemed to be a business need not be evaluated by a reporting entity to determine if the legal entity is a Variable Interest Entity (“VIE”)” unless any one of four conditions exist:

	-	The reporting entity, its related parties, or both participated significantly in the design or redesign of the legal entity;
	-	The legal entity is designed so that substantially all of its activities involve or are conducted on behalf of the reporting entity and its related parties;
	-	The reporting entity and its related parties provide more than half of the total of the equity, subordinated debt, and other forms of subordinated financial support to the legal entity; or
	-	The activities of the legal entity are primarily related to the securitizations or other forms of asset-backed financings or single-lessee leasing arrangements.

A VIE is an entity that either (a) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (b) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If we determine that we have operating power and the obligation to absorb losses or receive benefits, we consolidate the VIE as the primary beneficiary, and if not, we do not consolidate. The Company has not identified any VIEs as of August 31, 2016.

Intangible Assets

Effective September 1, 2014, the Company changed its method of computing amortization from a sales percentage method to the straight-line method for the intangible assets. An assessment of useful life and / or discounted cash flow of the intangible asset is made and where the value is overstated the value is impaired.

Income Taxes

The deferred tax assets or liabilities represent the future tax benefits or cost of those differences. The Company’s principal deferred tax items arise from net operating losses. Net operating losses approximate $18,800,000 which expire in the years 2030 through 2037. The net operating loss results in a deferred tax asset of $2,820,000. As future earnings are uncertain, the Company has provided a valuation allowance for the entire amount of the deferred tax asset.

The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are “more likely than not” of being sustained by the applicable tax authority. “More likely than not” is defined as greater than a 50% chance. The Company is delinquent on nearly all of its tax filings. As a result, there are presently no uncertain tax position and no reserves for uncertain tax positions.

The Company has no unrecognized tax benefits at February 29, 2016. The Company’s income tax returns are subject to examination by federal and state tax authorities. Due to the failure to file its tax returns, all prior tax years are open to examination. The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the balance sheet. There were no interest and penalties paid or accrued during the years ended February 29, 2016.

CV Sciences, Inc. FKA CannaVest Corp.

On December 23, 2014, the Company entered into a convertible promissory note for $1,200,000 with CannaVest Corp. The note represents $1,200,000 worth of raw material inventory to be obtained from CannaVest Corp. to use in the Company’s cannabidiol product formulations. The note accrues simple interest at a rate of 10% per annum and is due and payable in six months from the date of issue. The note cannot be prepaid. At any time, the outstanding principal amount of this note and all accrued but unpaid interest under this note can be converted into common shares at a price equal to the lesser of $0.02 per common share, the closing sale price, or the average of the lowest closing sale prices of the Company’s common shares during the five trading day period immediately preceding the date of such determination.

Should the Company default on this convertible promissory note, all outstanding obligations payable by the Company are immediately due and payable. In addition, CannaVest Corp. may exercise any other right, power or remedy permitted by law. Further, upon even of default, all unpaid obligations under this note shall bear interest at the rate of 12% per annum.

Warrant Agreement

In connection with the convertible promissory note dated December 23, 2014, the Company subsequently issued warrants to purchase 20,000,000 common shares at an exercise price of $0.02 per common share to Kisha Spendthrift Trust, an affiliate of CannaVest Corp. These warrants were issued on January 6, 2015. In exchange for these warrants, the Company shall have access to the technical and management staff of CannaVest Corp. for the development of products to be manufactured from cannabidiol sourced from CannaVest Corp.

On or about January 25, 2016, the Company entered into an Amendment No. 1 to the Convertible Promissory Note executed by and between the Company and CV Sciences, Inc (FKA Cannavest Corp. and referred to herein as “CVS”) dated December 23, 2014 (the “Note”), whereby the company and CVS agreed to terminate the Note upon the Company’s return of five containers of raw hemp oil to CVS. As of February 28, 2017 all remaining product had been returned to CVS, as the inventory did not meet quality standards and was returned for a reduction of the note balance.

It was determined that the remaining inventory should be written off as at February 29, 2016.

Subsidiary Companies

On March 17, 2014, MediHoldings, Inc. (“MediHoldings”), a Colorado corporation, was formed as a wholly-owned subsidiary of the Company.

On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly-owned subsidiary of the Company.

Both these subsidiaries as at August 31, 2016 had not traded and were inactive.

Related Party Transactions

Martin Tindall

Mr. Martin Tindall, assists the Company with business development activities through the Advisory Services Agreement with Kronos as discussed below. Mr. Tindall serves as the CEO of Kronos. Additionally, Mr. Tindall has provided new product development services through a New Product Development Agreement with Phoenix Pharms Capital Corporation, as discussed below. Mr. Tindall services as CFO and a Director of Phoenix Pharms Capital Corporation. Mr. Tindall also serves as a director of Phoenix Bio Pharmaceuticals Inc.

Kronos International Investments Ltd. (“Kronos”)

Sublease Agreement: Effective March 1, 2014, the Company entered into a Sublease Agreement with Kronos for a four (4) year term. Kronos’s CEO, Martin Tindall also provides advisory services to the Company. The monthly sublease rent is $2,500 per month. During the year ended February 29, 2016, the Company paid Kronos $7,500 in rent expense, and had previously paid security deposit of $1,250. In June 2015, the sublease was cancelled and the security deposit of $1,250 was offset against amounts owed to Kronos for advisory service fees. No payments were made to Kronos for the period March 1, 2016 and August 31, 2016.

Advisory Services: Effective March 1, 2014, the Company engaged Kronos to provide Advisory Services for a monthly retainer fee of $10,000 per month. The advisory services include and are not limited to accounting and corporate compliance, business development and strategic planning services, corporate advisory and operational oversight. For the year March 1, 2015 and February 29, 2016, expenses related to the Advisory Services were $120,000. There were no payments made for the period March 1, 2016 and August 31, 2016.

Phoenix Pharms Capital Corporation (“Phoenix Pharms”)

Related Party Loan: On September 18, 2014, the Company advanced Phoenix Pharms a total of $85,000 as a short term loan. The loan bears a simple interest rate of 8% and was due and payable on May 31, 2014. As of February 28, 2016, the Company has received principal payments totaling $26,425 including cash payment of $15,900, and expense offset $10,525. As of February 28, 2016, accrued interest on this loan is $2,687. As of August 31, 2016, the outstanding balance due the Company on this related party loan is $42,392.

Russell Stone: Mr. Russell Stone, the Company’s Chief Operating Officer, holds approximately 14% of the outstanding common shares of Phoenix Pharms Capital Corporation indirectly through a trust.

Lewis “Spike” Humer:

Mr. Humer, the interim Chief Executive officer and a director of the Company, serves as CEO and a director of Phoenix Bio Pharmaceuticals and CEO and a director of Phoenix Pharms Capital Corporation. As of August 2014, the Company began paying Mr. Humer a consulting fee of $1,500 per week. As of February 28, 2015, the Company has paid Mr. Humer $19,000 and has accrued a related party payable to Mr. Humer of $27,000. During the year from March 1, 2015 to February 29, 2016, a further $81,000 was accrued to Mr. Humer. There were no further accruals from March 1, 2016 to February 28, 2017.

Common Stock

The Company has authorized 990,000,000 shares of its common stock, $0.001 par value. On February 29, 2016 there were 25,845 shares of common stock on issue.

On March 4, 2016, YP Holdings LLC converted 2,400 series C preferred stock to 2,400 shares of common stock.

As at August 31, 2016, there were 28,245 shares of common stock issued and outstanding.

10.

Preferred Stock

On September 22, 2015, the Company amended and restated its Articles of Incorporation to create and authorize four (4) classes of preferred stock. The Company has authorized Series A, Series B, Series C and Series D Preferred Stock (the “Preferred Stock”).

Series A Preferred Stock:

Series A preferred shares have a par value of $0.0001, and are convertible into common shares at $1.00 per common share. Series A preferred shares rank senior to common stock with respect to the right to participate in distributions or payments in the event of liquidation, dissolution, or winding up of the Company. Holders of Series A preferred shares are entitled to a preferred return equal to the purchase price paid for such Series A preferred shares. Series A preferred shares do not have any voting rights.

Holders of Series A preferred shares are not entitled to preemptive rights to purchase stock in future stock offerings of the Company. Holders of Series A preferred shares have the right to register their unregistered stock when either the Company or another investor initiates a registration of the Company’s securities, and they have the right of co-sale. Holders of Series A preferred shareholders are not required to sell all of their Series A preferred shares on the same terms or conditions of a co-sale by a majority shareholder. There is no right of first refusal for Series A preferred shares.

Series B Preferred Stock:

Series B preferred shares have a par value of $0.0001, and are convertible into common shares at a rate of 100 common shares per preferred share. Series B preferred shares are entitled to cast 500 votes for each preferred share owned. Series B preferred shares are senior to common shares with respect to the right to participate in distributions or payments in the event of any liquidation, dissolution, or winding up of the Company, and holders of Series B preferred shares are entitled to receive a preferred return equal to the purchase price paid for such Series B preferred stock.

Holders of Series B preferred shares are entitled to preemptive rights to purchase stock in future offerings, and have the right to register their unregistered stock when either the Company or another investor initiates a registration of the Company’s securities. Holders do not have the right of co-sale, and are not required to sell all of their Series B preferred shares on the same terms or conditions of a co-sale by a majority shareholder. If any Series B preferred shareholder wishes to sell, transfer or otherwise dispose of any or all of their Series B preferred shares, the other Series B preferred shareholders shall not have a prior right to buy such Series B preferred shares.

Series C Preferred Stock:

Series C preferred shares have a par value of $0.0001, and are convertible into common shares at a rate of $1.00 per common share. Series C preferred shares are not entitled to any voting rights, unless such vote is to modify rights, preferences, privileges and restrictions granted to and imposed on Series C preferred shares. Series C preferred shares are senior to common shares and Series B preferred shares with respect to the right to participate in distributions or payments in the event of any liquidation, dissolution, or winding up of the Company, and holders of Series C preferred shares are entitled to receive a preferred return equal to the purchase price paid for such Series C preferred, which is deemed to be $600,000. If the closing price per share of the Company’s common shares is less than $1.00 for a period of five consecutive trading days, the YP Holdings will have the one-time right, exercisable at its discretion, to require that the conversion price of the shares become equal to 75% of the average closing bid price per shares for the five consecutive trading days immediately preceding the date that YP Holdings notifies the Company that it wishes to convert some or all of its Series C preferred shares into common shares. The reset shall not be available if the proceeds of the sale of converted common shares equals or exceeds $750,000. Should proceeds of the sale of converted common shares equal or exceed $1,000,000, any unconverted Series C preferred shares shall be returned to the Company for retirement. Converted common shares are subject to a leak-out agreement, and no more than 50,000 common shares may be sold by YP Holdings in any one month.

Holders of Series C preferred shares are entitled to receive a preferred return equal to 10% of the gross cash sales income received in the ordinary course of business. Holders are not entitled to preemptive rights to purchase shares in future offerings of the Company.

Holders of Series C preferred shares have the right to register their unregistered shares when either the Company or another investor initiates a registration of the Company’s securities. Holders have the rights of co-sale, and are not required to sell all of their Series C preferred shares on the same terms or conditions of a co-sale by a majority shareholder. If any Series C preferred shareholder wishes to sell, transfer, or otherwise dispose of any or all of their Series C preferred shares, other Series C preferred shareholders shall not have a prior right to buy such shares.

Series D Preferred Stock

Series D preferred shares have a par value of $0.0001, and are convertible into common shares at a conversion rate of $1.00 per common share. Series D preferred shares rank senior to common shares and the Series B preferred shares. In the event of any liquidation, dissolution, or winding up of the Company, holders of Series D preferred shares shall be entitled to receive a preferred return equal to the purchase price paid for such Series D preferred shares after payment of the preferred returns relating to the Series A and C preferred shares. Series D preferred shares are not entitled to voting rights.

Holders of Series D preferred shares shall be entitled to receive a preferred return equal to 10% of the Gross Cash Sales Income received in the ordinary course of business. Upon issue of the dividend, the value of such shares shall be deemed to be retired. Holders of Series D preferred shares are not entitled to preemptive rights to purchase stock in future offerings of the Company. Holders of Series D preferred shares have the right to register their unregistered stock when either the Company or another investor initiates a registration of the Company’s securities. Holders of Series D preferred shares have the right of co-sale, but they are not required to sell all of their Series D preferred shares on the same terms or conditions of a co-sale by a majority shareholder.

As at February 28, 2016, Phoenix Bio Pharmaceuticals Corporation had been issued 2,000,000 Series B Preferred Shares. YP Holdings, LLC had been issued 1,000,000 Series C Preferred Shares. but had converted 2,000 into common shares and therefore owned 998,000 Series C Preferred Shares.

On March 4, 2016, YP Holdings, LLC converted 2,400 series C preferred stock to 2,400 shares of common stock.

As at August 31, 2016, Phoenix Bio Pharmaceuticals Corporation held 2,000,000 Series B Preferred Shares. YP Holdings, LLC had been issued 1,000,000 Series C Preferred Shares. but had converted 4,400 into common shares and therefore held 995,600 Series C Preferred Shares.

11.

Common Stock Options

As at August 31, 2016 and February 29, 2016 there were no common stock options on issue.

12.

Convertible Promissory Note

On June 24, 2014, the Company entered into a securities purchase agreement with Typenex Co-Investment, LLC, a Utah limited liability company. Under this agreement, the Company has issued a secured convertible promissory note in the original principal amount of $1,105,000, deliverable in eleven tranches (the “Typenex Note”). On the closing date, Typenex delivered the initial cash purchase price of $150,000, plus any interest, costs, fees or charges accrued under the Typenex Note, including the original issue discount of $20,000. The outstanding principal and accrued and unpaid interest on the Typenex Note is convertible at any time into shares of common stock at a conversion price of $1.00, subject to adjustment as described below (the “Lender Conversion Price”). As of June 24, 2014, the Company evaluated the Beneficial Conversion Feature under this note and determined as of June 24, 2014, there was no beneficial conversion feature as the Lender Conversion Price exceeded the fair market value of the Company’s common stock.

As of November 30, 2014, the company has received net proceeds of $135,000 related to this convertible promissory note, representing $150,000 less financing costs of $15,000. During the nine months ended November 30, 2014 the Company has recorded interest expense of $7,725, and amortization expense of $554,413 related to the amortization of the original issue discount and the full-value of the warrant discussed below ($552,500).

Each subsequent tranche will be in the amount of $85,000, plus any interest, costs, fees or charges accrued thereon under the terms of the Typenex Note, including the original issuer discount of $8,500. Each tranche will be accompanied by its own secured investor note (the “Investor Notes”). The Company has agreed to pay $5,000 to cover Typenex’s legal fees, accounting costs, due diligence, monitoring and other transaction costs in connection with the purchase and sale of the Typenex Note. All loans received bear an interest rate of 10% per annum. The loan is due 23 months after the initial cash purchase price is delivered to the Company. Typenex has pledged a 40% membership interest in Typenex Medical, LLC to secure its obligations under all of the Typenex Notes.

A warrant to purchase shares of the Company has been issued to Typenex as of June 24, 2014. This warrant grants Typenex the ability to purchase a number of fully paid and non-assessable shares of the Company’s stock, par value $0.001, equal to $552,500 divided by the market price. This warrant is issued pursuant to the terms of the securities purchase agreement as described above.

Provided there is an outstanding balance, the Company will pay an installment amount equal to $61,388.89 plus any accrued and unpaid interest on the installment due date, which is six months after the initial loan disbursement. This installment amount is the maximum that must be paid on any given installment due date, and is limited by the amounts owed. This amount can be converted at the lesser of either the lender conversion price or at 70% of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion. Should the average trading price be less than $0.35 during any such period, then the conversion factor will be reduced to 65% for all future conversion, additionally the conversion price will be reduced by 5% if the Company’s common stock is not available for DWAC. Should the Company decide to prepay this amount, there is a prepayment premium equal to 125% of the outstanding balance of the Typenex Note. Should the prepayment premium not be paid within 2 days of the prepayment notice, the Company forfeits its right to prepay the Typenex Note.

Under this agreement, Typenex has the right at any time after the purchase price date until the outstanding balance has been paid in full to convert any or all of the outstanding balance into shares of the Company’s common stock under the following formula: the number of shares issued equals the amount being converted divided by $1. These shares must be delivered to Typenex within three trading days of the conversion notice being given to the Company. Should any shares be sold to Typenex or any third party at a value that is less than the effective lender conversion price, then the lender conversion price will be reduced to equal such lower issuance price. The effective lender conversion price will also be adjusted as needed upon any forward or reverse split of the Company’s shares. Should the Company fail to deliver the shares in a timely manner, a late fee of the greater of $500 per day and 2% of the applicable lender conversion share value rounded to the nearest multiple of $100 will be assed for each day after the third that the Company is late (though not exceeding 200% of the applicable lender conversion share value.

In the event of a default, the Typenex Note may be accelerated by Typenex by providing written notice to the Company. The outstanding balance is immediately due and payable at the greater of the outstanding balance divided by the installment conversion price, or the default effect, which is calculated by multiplying the conversion eligible outstanding balance by 15% for each major default or 5% for each minor default and then adding the resulting product to the outstanding balance as of the date of default. In addition, an interest rate of the lesser of 22% per annum (or the maximum rate permitted under law) will be applied to the outstanding balance. Typenex is prohibited from owning more than 4.99% of the Company’s outstanding shares, unless the market capitalization of the Company’s common stock is less than $10,000,000, in which case Typenex is prohibited from owning more than 9.99% of the Company’s outstanding shares.

On a date that is 23 trading days from each date that the Company delivers conversion shares to Typenex, there is a true-up date in which the Company will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.

Notice of Default – on January 9, 2015, the Company received a Notice of Default from Typenex under the Convertible Promissory Note described in Note 12 above. In the letter, the noteholder described two major defaults where the Company failed to meet its obligations under the Typenex Note. The first default was triggered on December 16, 2014 related to a request from the noteholder to increase the number of shares reserved for issuance under the Typenex Note on the books of the Company’s transfer agent. The second default was triggered on December 27, 2014, when the Company failed to make its first installment payment of $61,888.89 according to the terms of the Typenex Note. Each default triggered a penalty of 115% of the then outstanding principal and accrued and unpaid interest and triggers the interest rate to 22%. As of January 9, 2015, the outstanding principal, accrued interest and accrued penalties on the Typenex Note was $239,483.61. On January 23, 2015, the Company satisfied its first default by instructing its transfer agent to reserve a total of 50,925,000 shares of common stock covering the potential conversion of the original principal value of the Typenex Note ($1,100,000) plus common shares issuable upon the exercise of warrants underlying the Typenex Note. On February 12, 2015, the Company received a notice from Typenex waiving the penalties on the December 16, 2014 default and waived $26,755.16 of penalties imposed on December 16, 2014. Under the terms of the Typenex Note, the Lenders Conversion Price will reset to 60% of the average of the three lowest closing bid prices of the Company’s common stock in the 20 days prior to conversion. As of December 16, 2014, the Company has re-evaluated the beneficial conversion feature under the Typenex Note and has recorded a liability for the beneficial conversion feature totaling $230,392. This discount will be amortized over the remaining life of the Typenex Note.

On February 3, 2015, the Company exercised its borrower offset right under the Typenex Note. Through this offset right, the Company is entitled to deduct and offset any amount owing by Typenex under the initial securities purchase agreement dated June 24, 2014 from any amount owed by the Company under the note. The combined balance of the secured investor notes and the investor notes as of the January 28, 2015 offset date was $890,800. In addition, the note balance prior to the offset included $85,000 of unearned original issue discounts.

In conjunction with the Company’s exercise of its offset right, the Company and Typenex each hereby acknowledge that the secured investor notes and the investor notes were offset against the Company balances owed under the note as of the offset date, and as a result thereof, each of the secured investor notes and the investor notes is deemed to have been paid in full and are now cancelled and terminated and the Company balance owed under the note has been reduced to $218,028.47 as of the offset date. Additionally, the Company specifically acknowledges that Typenex has no further obligations under any of the secured investor notes and investor notes.

Further, the Company acknowledges that the investor pledge agreement, dated June 24, 2014, and all security interests granted thereunder with respect to the collateral (as defined in the investor pledge agreement) have terminated and all such security interests shall be deemed released.

Notice of Conversion – Between February 28, 2016 and August 31, 2016, the Company has received no further conversion notices from its noteholder on the Typenex Note to convert principal on the Typenex Note into shares of the Company’s Common Stock at a market price as defined by the Typenex Note.

13.

Securities Purchase Agreement

On September 17, 2014, the Company entered into a securities purchase agreement with YP Holdings, LLC. YP Holdings, LLC has no material relationship with the Company other than with respect to this agreement.

Under this agreement, the purchasers will be purchasing units of one common share and two warrants to purchase common shares for $0.09 per unit, for a total of $600,000. The common shares have a par value of $0.001 per share. The warrants are exercisable for five years from the date of issuance and shall have an initial exercise price equal to $0.20. As a result of this agreement, the Company issued 667 (6,666,667 pre-split) common shares and 1,333 (13,333,333 pre-split) warrants to the purchasers. On August 29, 2014 and September 17, 2014, the Company received gross proceeds of $100,000 and $500,000, respectively and has recorded financing fees of $18,000 and $52,000, related to this agreement.

The warrants can be exercised by paying the price for shares as stipulated by the warrant, or through cashless exercise, through which the purchaser will be issued a number of shares equal to the number of warrant shares applied to the subject exercise multiplied by the current market price on the date of conversion minus the exercise price on that date. This total is then divided by the current market price on the date of conversion. The cashless exercise may only be exercised after six months have passed from the original issuance of the warrants.

The purchaser has waived the clause prohibiting conversion of warrants into common shares if that would result in the purchaser owning in excess of 4.99% of the outstanding shares. A second clause prohibits the conversion of warrants if the purchaser owns in excess of 9.99% of the outstanding common shares. This clause can be waived by the purchaser providing notice of waiver.

The Company has agreed to pay a flat $20,000 to YP Holdings, LLC to reimburse them for the fees and expenses incurred by it in connection with its due diligence review of the Company and the preparation, negotiation, executive, delivery and performance of the agreement.

The two parties also entered into a registration rights agreement. Under this agreement, the Company will prepare and file a registration statement on Form S-1 in order to register all shares issued under the securities purchase agreement. The Company will keep the registration statement continuously effective for a period of two years following the effective date of the registration statement. The Company will pay all reasonable fees and expenses incurred with respect to this agreement. Unless previously agreed to in writing, the Company may not register any shares other than those intended to be sold under this agreement.

Should the Company fail to comply with the registration rights agreement, the Company agrees to pay liquidated damages to YP Holdings, LLC equal to 3% of the purchase price of the common shares paid by the purchaser for the first 30 day period, and 2% of such purchase price for each subsequent 30 day period. These payments are payable upon demand in cash.

Pursuant to the registration rights agreement, the Company agreed to several lock-up agreements between itself and four shareholders of the Company: Phoenix Bio Pharmaceuticals Corporation, Ronald Lusk, Lewis Humer, and Caduceus Industries LLC. Under these agreements, each shareholder has agreed that they will not offer, pledge, sell, contract to sell, grant any options for sale or transfer, distribute or dispose of, directly or indirectly, any shares of the Company for a 90 day period following the date that the registration statement is declared effective.

Additionally, on September 16, 2014, the Company issued warrants to purchase 53 (533,333 pre-split) common shares to consultants for services rendered. The warrants expire five years from the date of issuance and are exercisable for $0.20 per share. The Company has valued these warrants using the Black Scholes option pricing model and has recorded expense related to the issuance of these warrants totaling $104,578 during the quarter ended May 31, 2014.

14.

Subsequent Events

On September 15, 2016, Typenex Co-Investment, LLC exercised part of their warrant and were issued 2,822 shares of common stock.

On September 21, 2016, the registrant dismissed Fruci & Associates II, PLLC as their registered independent public accountant. On September 21, 2016, the Company’s Board of Directors approved the engagement of BMKR, LLP to provide auditing services on a prospective basis, and to perform a full audit of the Company’s books and records for the years ended February 29, 2016, February 28, 2017 and February 28, 2018.

On March 8, 2017, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from MediJane Holdings, Inc. to Stem Bioscience, Inc.

On May 31, 2018, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from Stem Bioscience, Inc. to Phoenix Life Science International Limited.

Pursuant to the Agreement and Plan of Merger, dated as of September 18, 2018 as (The “Merger Plan” by and between Phoenix Life Sciences International Limited, a Nevada Corporation (the “Company”) and Phoenix Life Sciences International Limited, a Canadian Corporation (“PLSI CA”), the Company completed its merger with PLSI CA, with the Company as the surviving entity.

On September 18, 2018, the Company’s Board of Directors announced the finalized consolidation activities of Phoenix Life Sciences International Limited with Stem Biosciences, Inc., Blue Dragon Ventures, and the MediJane Brand, and that the Company’s common stock would trade publicly under the symbol MJMD.

On September 21, 2018, the Company announced it had obtained consent from the holder, Phoenix Bio Pharmaceuticals Corporation for the cancellation of 2,000,000 Preferred Series B shares in the Company in connection with the restructure of the Company and merger with Phoenix Life Sciences International Limited, a Canadian Corporation.

On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director.

On or about June 24, 2014, the Company entered into a Convertible Promissory Note with a face value of $1,105,000 (the “Note”) by and between the Company and Typenex Co-Investment, LLC (“Typenex”). On or about April 19, 2018, the Phoenix Life Sciences International Ltd, a Canadian Corporation (“PLSI CA”) acquired the entirety of the Notes outstanding principal and interest balance from Typenex. Upon the completion of the merger, that Note was conveyed to the Company.

On September 22, 2018, the Company’s Board of Directors resolved to deem the acquired Notes principal balance satisfied, and to terminate the Note and any and all rights and obligations arising thereunder, including without limitation the cancellation of all Warrants issued to Typenex under the Note.

On September 24, 2018, the Company issued 30,502,375 shares of common stock bearing the restricted legend without registration (the “Issued Shares”). Of these, 29,802,375 shares were issued in reliance on Rule 802 under the Securities Act in a 1:1 share exchange related to the merger of PLSI CA and the company as described above, and 700,000 shares were issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. All of the Issued Shares were issued in private transactions, and the company received no proceeds from the Issued Shares. The Issued Shares, in conjunction with the 47,571 shares of common stock previously issued by the Company, brings the current issued and outstanding share count to 30,549,946.

On October 3, 2018, the following persons were appointed to the Board of the Company, Stephen Cornford, Martin Tindall as Chief Executive Officer, Janelle Marsden as Managing Director and Geoffrey Boynton as Chief Financial Officer. Lewis “Spike” Humer stepped down from his executive role but remains a Director.

On October 3, 2018, the Company agreed to issue 48,000 shares of restricted common stock to KHAOS Media Group as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act for services previously rendered and invoiced between March and December 2014.

On November 2, 2018, FINRA confirmed the name change and change of symbol to “PLSI”.

On November 9, 2018, the Company announced that 2,000,000 Series C Preferred Stock had been cancelled and all convertible debt had been retired. There was no outstanding preferred stock on issue as at this day.

On December 4, 2018, the Company issued 229,600 common shares as part of settlement agreements.

On December 17, 2018, the Company issued 675,028 common shares which included 191,668 common shares as part of settlement agreements and 483,360 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act.

On January 11, 2019, the Company issued 500,600 common shares to YP Holding, LLC. as part of a settlement agreement.

On January 15, 2019 the Company issued 54,580 common shares which included 53,500 common shares as part of settlement agreements and 1,080 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act.

On February 20, 2019 the Board of the Company appointed Michael Gobel, who has long and distinguished career in corporate finance in Australia, as a non-executive Director.

On February 26, 2019 the Company issued 315,928 common shares which included 5,460 common shares as part of settlement agreements, 126,750 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act and 183,718 for cash consideration.

On April 2, 2019 the Company issued 151,216 common share for cash consideration.

Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) commenced the consolidation of business in 2018. During that time, affiliates of the Company provided certain working capital and covering of costs related to the consolidation. Subsequently the Company has entered into subscription agreements with certain affiliates and key non-affiliate investors to provide a total of approximately USD $2.1million of financing. Shares of common stock issued for this total financing represent approximately 800,000. The key non-affiliate investor who had previously entered into a subscription agreement to purchase USD $20 million of shares at $10 per share with Phoenix Life Sciences International Limited Canada has entered into an agreement to exchange the subscription for warrants to purchase Company common stock at a price of $10, with the purchases to be completed by December 31, 2019.

Further, as part of the merger and consolidation, Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) entered into settlement agreements with former investors, employees and contractors whereby their debt, shares held in entities subject of the consolidation, or outstanding amounts were settled in exchange for a full release of claims and the Company issuing approximately eight (8) million shares and the assumption of approximately $2 million of settlements payable. The purpose of the consolidation, in addition to providing the deemed necessary relationships and contracts for the Company to execute on its strategy, was to settle any potential claim or liability to ensure that the Company was not subject to any claims by former investors, employees and contractors.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

The Company was incorporated in the State of Nevada on April 21, 2009, under the name Mokita Exploration, Ltd. On February 5, 2010, the Company filed a Certificate of Amendment to the Articles of Incorporation changing our name to Mokita, Inc. On February 27, 2014, there was a change of control of the Company. On February 28, 2014, our board of directors and a majority of holders of the Company’s voting securities approved a change of name of the Company to MediJane Holdings Inc. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on March 4, 2014. A Certificate of Correction was subsequently filed with the Nevada Secretary of State on March 6, 2014 to correct a spelling error in the Company’s new name. These amendments have been reviewed by FINRA and were approved for filing with an effective date of March 10, 2014. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on March 10, 2014 under our new ticker symbol “MJMD”.

After the change of control on February 27, 2014, the Company became a medical delivery systems company with a pharmaceutical approach to cannabinoid treatment of various illnesses with medical cannabis, currently being launched in Colorado and California.

Recent Developments

With the merger by and between Phoenix Life Sciences International Limited, a Nevada Corporation (the “Company”) and Phoenix Life Sciences International Limited, a Canadian Corporation (“PLSI CA”), whereby the Company completed its merger with PLSI CA on September 18, 2018, with the Company as the surviving entity, the Company will continue to pursue a pharmaceutical approach to cannabinoid treatment of various illnesses with medical cannabis.

On October 10, 2018, the Company announced it had received approval from the Vanuatu Investment Promotion Authority (VIPA) to establish operations in the Republic of Vanuatu and manufacture botanical pharmaceutical products.

Consolidated Results of Operations

The results of the business as a medical cannabis sales and distribution company for the three months and six months ended August 31, 2016.

Revenue for the three months ended August 31, 2016 and 2015 was $0 and $15,975 respectively. Revenues for the six months ended August 31, 2016 and 2015 were $0 and $18,410. Revenues and related expenses were primarily from sale of CBD products.

Cost of Sales for the three months ended August 31, 2016 and 2015 was $0 and $5,035. Cost of Sales for the six months ended August 31, 2016 and 2015 were $0 and $5,933 respectively.

Product development expense for the three months ended August 31, 2016 and 2015 was $0 and $70,000 respectively. Product development expenses for the six months ended August 31, 2016 and 2015 were $0 and $100,000 respectively. Product development expenses in the 2015 period represent payments to Phoenix Bio Pharm for the product development of branded products of the Company.

Sales and marketing expenses for the three months ended August 31, 2016 and 2015 were $0 and $6,306. Sales and marketing expenses for the six months ended August 31, 2016 and 2015 were $0 and $14,953, respectively. Sales and marketing expenses have been curtailed due to the lack of funds.

Operations expenses for the three months ended August 31, 2016 and 2015 were $0. Operations expenses for the six months ended August 31, 2016 and 2015 were $0 and $1,745, respectively. The decrease in operating expenses during the 2016 period are due to reduced activities due to limited funded.

General and administrative expenses for the three months ended August 31, 2016 and 2015 were $1,273 and $15,080 respectively. General and administrative expenses for the six months ended August 31, 2016 and 2015 were $3,253 and $30,876. General and administrative expenses generally include costs for running the company’s administrative office. The decrease this year has been due to limited funds.

Professional fees for the three months ended August 31, 2016 and 2015 were $0 and $79,437 respectively. Professional fees for the six months ended August 31, 2016 and 2015 were $330 and $217,712, respectively. Professional fees consist of cost of financing, legal, accounting, consulting and advisory services.

Lease operating expenses for the three months ended August 31, 2016 and 2015 were $0. Lease operating expenses for the six months ended August 31, 2016 and 2015 were $0 and $7,500, respectively.

Other income and expenses for the three months ended August 31, 2016 were net income of $162,305 and for the three months ended August 31, 2015 were net expenses of $19,582, for interest, amortization of a convertible note and loss or gain on a derivative liability. Other income and expense for the six months ended August 31, 2016 and 2015 were net income of $49,531 and a net loss of $43,389, respectively.

Net profit for the three months ended August 31, 2016 was $161,031 and a net loss for 3 months ended August 31, 2015 of $179,735. Net profit for the six months ended August 31, 2016 was $45,948 and a net loss for 6 months ended August 31, 2015 of $403,090.

Liquidity and Capital Resources

At August 31, 2016, the Company had a cash balance of $2,519 compared with $7,591 at February 28, 2016. The decrease in cash was cash used for operating expenses as described above partially offset by repayment of some of a note payable by a related party.

Cash flow from Operating Activities. During the six months ended August 31, 2016, the Company used $16,172 in cash for operating activities for its current operations. During the six months ended August 31, 2015, the Company used $129,084 for operating activities.

Cash flow from Investing Activities. During the six months ended August 31, 2016 and August 31, 2015, the Company received $11,100 and $8,970, respectively, for investing activities. Cash Flows from investing activities in the period ended August 31, 2016 represents partial repayment of the Company’s loan with its affiliate Phoenix Pharms Capital Corporation.

Cash flow from Financing Activities. During the six months ended August 31, 2016 and 2015, the Company received proceeds of $0 and $111,250 respectively.

Going Concern

We have not attained profitable operations and are dependent upon the commencement of the sale of our products and obtaining financing to increase the production and development of our products. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

Future Financings

We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund planned acquisitions and exploration activities.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management’s estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Use of Estimates. The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Stock-based Compensation. The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Based Compensation and ASC 505-50 - Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

Revenue Recognition. The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin Topic 13 when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection is probable. The Company assesses whether the fee is fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. Up-front engagement fees are recorded as deferred revenue and amortized to income on a straight-line basis over the term of the agreement, although the fee is due and payable at the time the agreement is signed or upon annual renewal. Payments related to substantive, performance-based milestones in an agreement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreement when they represent the culmination of the earnings process.

Recent Accounting Pronouncements

The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Contractual Obligations

As a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable for smaller reporting companies.

Item 4. Controls and Procedures

During the period ended August 31, 2016, there were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of August 31, 2016. We do not have sufficient segregation of duties within accounting functions, which is a basic internal control. Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Based on this evaluation, our chief executive officer and chief financial officer have concluded such controls and procedures to be not effective as of August 31, 2016 to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms and to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Remediation Plan

We will aggressively recruit experienced professionals to ensure that we include all necessary disclosures in our filings with the Securities and Exchange Commission. Although we believe that this corrective step will enable management to conclude that the internal controls over our financial reporting are effective when the staff is trained, we cannot assure you these steps will be sufficient. We may be required to expend additional resources to identify, assess and correct any additional weaknesses in internal control.

We are unable to remedy our controls related to the inadequate segregation of duties until we receive financing to hire additional employees.

PART II – OTHER INFORMATION

Item 1.

Legal proceedings

Except as disclosed below, the Company, is not involved in any material active or pending legal proceedings. The Company has entered into settlement agreements with all known potential or asserted claims. The Company is currently involved in two disputes relating to deposits being due on proposed property purchases. The attorneys representing the Company in Vanuatu maintain that the claims are spurious, as the related contracts were never validly executed and at no time were unconditional, negating any obligation by the Company to pay the deposit. As at the date of this filing, the Company has moved to dismiss both claims, and is confident that the matters will be resolved in its favor.

Item 1A.	Risk Factors Not applicable for smaller reporting companies

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds

	During the period 1 March 2016 to 31 August 2016, 2,400 shares of common stock were issued pursuant to conversion of 2,400 Series C Preferred stock.

Item 3.	Defaults Upon Senior Securities.

	None

Item 4.	Mine Safety Disclosures

	Not applicable

Item 5.	Other Information

	None

Item 6.	Exhibit

Exhibit 31.1*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2*	Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2*	Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS	XBRL Taxonomy Extension Schema Document
101.SCH	XBRL Taxonomy Extension Calculation Linkbase Document
101.CAL	XBRL Taxonomy Extension Definition Linkbase Document
101.DEF	XBRL Taxonomy Extension Label Linkbase Document
101.LAB	XBRL Taxonomy Extension Presentation Linkbase Document
101.PRE	XBRL Instance Document

*Filed herewith.

**Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHOENIX LIFE SCIENCES INTERNATIONAL LIMITED

/s/ Martin H. Tindall		Dated April 15, 2019
Martin H. Tindall
Chief Executive Officer


/s/ Geoffrey K. Boynton		Dated April 15, 2019
Geoffrey K. Boynton
Chief Financial Officer
Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

/s/ Martin H. Tindall		Dated April 15, 2019
Martin H. Tindall
Chief Executive Officer
Director

EX-31.1 2 ex31-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Phoenix Life Sciences International Limited 10-Q

EXHIBIT 31.1

302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Martin H. Tindall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Phoenix Life Sciences International Limited;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: April 15, 2019

/s/ Martin H. Tindall

Martin H. Tindall

Chief Executive Officer

EX-31.2 3 ex31-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

Phoenix Life Sciences International Limited 10-Q

EXHIBIT 31.2

302 CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Geoffrey K. Boynton, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Phoenix Life Sciences International Limited;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: April 15, 2019

/s/ Geoffrey K. Boynton

Geoffrey K. Boynton

Chief Financial Officer

EX-32.1 4 ex32-1.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Phoenix Life Sciences International Limited 10-Q

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Phoenix Life Sciences International Limited (the “Company”) on Form 10-Q for the period ended August 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin H. Tindall, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Martin H. Tindall

Martin H. Tindall

Chief Executive Officer

April 15, 2019

EX-32.2 5 ex32-2.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

Phoenix Life Sciences International Limited 10-Q

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Phoenix Life Sciences International Limited (the “Company”) on Form 10-Q for the period ended August 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Geoffrey K. Boynton, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Geoffrey K. Boynton

Geoffrey K. Boynton

Interim Chief Financial Officer

April 15, 2019

EX-101.INS 6 plsi-20160831.xml XBRL INSTANCE DOCUMENT 0001493212 2016-03-01 2016-08-31 0001493212 2019-02-28 0001493212 2016-08-31 0001493212 2016-02-29 0001493212 us-gaap:SeriesBPreferredStockMember 2016-08-31 0001493212 us-gaap:SeriesBPreferredStockMember 2016-02-29 0001493212 us-gaap:SeriesCPreferredStockMember 2016-08-31 0001493212 us-gaap:SeriesCPreferredStockMember 2016-02-29 0001493212 2016-06-01 2016-08-31 0001493212 2015-06-01 2015-08-31 0001493212 2015-03-01 2015-08-31 0001493212 2015-02-28 0001493212 2015-08-31 0001493212 us-gaap:MajorityShareholderMember plsi:LicensingAgreements1Member 2015-01-05 0001493212 us-gaap:MajorityShareholderMember us-gaap:SeriesBPreferredStockMember 2015-11-03 2015-11-04 0001493212 2015-10-21 2015-10-22 0001493212 2015-10-20 0001493212 2015-10-22 0001493212 us-gaap:MaximumMember 2016-03-01 2016-08-31 0001493212 us-gaap:MinimumMember 2016-03-01 2016-08-31 0001493212 plsi:WarrantsMember 2015-01-06 0001493212 us-gaap:ConvertibleNotesPayableMember 2014-12-23 0001493212 us-gaap:AffiliatedEntityMember 2015-06-01 2015-06-30 0001493212 plsi:AffiliatedEntity1Member 2014-09-15 2014-09-18 0001493212 us-gaap:AffiliatedEntityMember 2014-03-01 2014-03-31 0001493212 us-gaap:DirectorMember 2014-08-13 2014-08-14 0001493212 us-gaap:DirectorMember 2016-08-31 0001493212 us-gaap:DirectorMember 2016-02-29 0001493212 plsi:AffiliatedEntity1Member 2015-03-01 2016-02-28 0001493212 plsi:AffiliatedEntity1Member plsi:NewProductDevelopmentAgreementMember 2015-03-01 2015-08-31 0001493212 us-gaap:AffiliatedEntityMember 2016-03-01 2016-08-31 0001493212 plsi:AffiliatedEntity1Member 2016-02-28 0001493212 plsi:AffiliatedEntity1Member 2014-09-18 0001493212 plsi:AffiliatedEntity1Member 2016-08-31 0001493212 us-gaap:SeriesAPreferredStockMember 2016-08-31 0001493212 us-gaap:SeriesAPreferredStockMember 2016-03-01 2016-08-31 0001493212 us-gaap:SeriesDPreferredStockMember 2016-08-31 0001493212 us-gaap:SeriesCPreferredStockMember plsi:YPHoldingLLCMember 2016-08-31 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-06-23 2014-11-30 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-11-30 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-03-01 2014-11-30 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2014-06-23 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-06-23 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember us-gaap:MaximumMember 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember us-gaap:MinimumMember 2014-06-24 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember plsi:DateOfNoticeMember 2015-01-09 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2015-01-28 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember plsi:DateOfNoticeMember 2015-01-23 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2014-12-16 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember 2015-02-11 2015-02-12 0001493212 plsi:SecuritiesAgreementsMember us-gaap:CommonStockMember 2014-09-14 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember us-gaap:WarrantMember 2014-09-15 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember us-gaap:CapitalUnitClassAMember 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember us-gaap:CapitalUnitClassAMember 2014-09-12 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember 2014-09-13 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember 2014-08-28 2014-08-29 0001493212 plsi:SecuritiesAgreementsMember us-gaap:MaximumMember 2014-09-17 0001493212 plsi:SecuritiesAgreementsMember us-gaap:MinimumMember 2014-09-17 0001493212 us-gaap:SubsequentEventMember 2019-04-01 2019-04-02 0001493212 us-gaap:SubsequentEventMember plsi:SettlementAgreementsMember 2019-02-25 2019-02-26 0001493212 us-gaap:SubsequentEventMember 2019-02-25 2019-02-26 0001493212 us-gaap:SubsequentEventMember 2019-01-14 2019-01-15 0001493212 us-gaap:SubsequentEventMember plsi:SettlementAgreementsMember 2019-01-14 2019-01-15 0001493212 us-gaap:SubsequentEventMember plsi:YPHoldingLLCMember plsi:SettlementAgreementsMember 2019-01-10 2019-01-11 0001493212 us-gaap:SubsequentEventMember plsi:SettlementAgreementsMember 2018-12-16 2018-12-17 0001493212 us-gaap:SubsequentEventMember 2018-12-16 2018-12-17 0001493212 us-gaap:SubsequentEventMember plsi:SettlementAgreementsMember 2018-12-03 2018-12-04 0001493212 us-gaap:SubsequentEventMember us-gaap:SeriesCPreferredStockMember 2018-11-08 2018-11-09 0001493212 us-gaap:SubsequentEventMember plsi:KHAOSMediaGroupMember us-gaap:RestrictedStockMember 2018-10-02 2018-10-03 0001493212 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2018-09-24 0001493212 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember plsi:PhoenixLifeSciencesInternationalLimitedMember 2018-09-23 2018-09-24 0001493212 us-gaap:SubsequentEventMember us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2018-09-23 2018-09-24 0001493212 us-gaap:SubsequentEventMember plsi:SubscriptionAgreementsMember 2019-04-01 2019-04-02 0001493212 us-gaap:SubsequentEventMember plsi:SubscriptionAgreementsMember plsi:NonAffiliateInvestorMember 2019-04-01 2019-04-02 0001493212 us-gaap:SubsequentEventMember plsi:SubscriptionAgreementsMember plsi:NonAffiliateInvestorMember 2019-04-02 0001493212 us-gaap:AffiliatedEntityMember 2015-03-01 2016-02-29 0001493212 us-gaap:DirectorMember 2015-02-27 2015-02-28 0001493212 plsi:MrRussellStoneMember 2016-08-31 0001493212 us-gaap:SeriesCPreferredStockMember plsi:YPHoldingLLCMember 2016-03-03 2016-03-04 0001493212 plsi:YPHoldingLLCMember us-gaap:SeriesBPreferredStockMember 2016-03-03 2016-03-04 0001493212 us-gaap:SeriesCPreferredStockMember 2016-03-01 2016-08-31 0001493212 us-gaap:SeriesCPreferredStockMember plsi:YPHoldingLLCMember 2016-03-01 2016-08-31 0001493212 us-gaap:MajorityShareholderMember us-gaap:SeriesBPreferredStockMember 2016-02-28 0001493212 us-gaap:SeriesCPreferredStockMember plsi:YPHoldingLLCMember 2016-02-28 0001493212 us-gaap:SeriesCPreferredStockMember plsi:YPHoldingLLCMember 2016-02-27 2016-02-28 0001493212 us-gaap:CommonStockMember plsi:YPHoldingLLCMember 2016-02-27 2016-02-28 0001493212 us-gaap:MajorityShareholderMember us-gaap:SeriesBPreferredStockMember 2016-03-01 2016-08-31 0001493212 us-gaap:SeriesBPreferredStockMember 2016-03-01 2016-08-31 0001493212 plsi:SecuritiesAgreementsMember us-gaap:ConvertibleDebtMember plsi:DateOfNoticeMember 2015-01-08 2015-01-09 0001493212 plsi:ConsultantsMember us-gaap:WarrantMember 2014-09-15 2014-09-16 0001493212 plsi:ConsultantsMember us-gaap:WarrantMember 2014-09-16 0001493212 plsi:ConsultantsMember us-gaap:WarrantMember 2014-03-01 2014-05-31 0001493212 us-gaap:SubsequentEventMember plsi:TypenexCoInvestmentLLCMember plsi:WarrantsMember 2018-09-14 2018-09-15 0001493212 us-gaap:SubsequentEventMember 2018-09-24 0001493212 us-gaap:MajorityShareholderMember us-gaap:SeriesBPreferredStockMember 2018-09-20 2018-09-21 0001493212 us-gaap:SubsequentEventMember plsi:SubscriptionAgreementsMember plsi:NonAffiliateInvestorMember plsi:WarrantsMember 2019-04-02 0001493212 plsi:PhoenixLifeSciencesInternationalLimitedMember plsi:SettlementAgreementsMember 2016-03-01 2016-08-31 0001493212 plsi:PhoenixLifeSciencesInternationalLimitedMember plsi:SettlementAgreementsMember 2016-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure plsi:Number Phoenix Life Sciences International Limited. 0001493212 10-Q 2016-08-31 PLSI false --02-28 No 2017 Q2 32584582

240771

256943

240771

256943

238252

249352

2519

7591

9400

473

1308559

1370679

243579

397512

230932

297708

193306

767272

779861

267219

500053

512642

240771

256943

-1067788

-1113736

-18773091

-18819039

17704975

17704977

200

100

0.001

990000000

28245

25845

276000000

50000

28245

25845

501242594

50125

30549946

2000000

995600

998000

1000000

2000000

1000000

2000000

995600

998000

10940

12477

5035

5933

15975

18410

-3583

-1273

-159883

-359701

3583

1273

170823

372178

330

79437

217712

3253

1273

15080

30876

1745

6306

14345

70000

100000

45948

161031

-179735

-403090

153933

178576

28022

94537

2435

46049

7830

101967

16271

41024

86140

980

2093

28206

28245

258030222

364290048

1.63

5.7

1.63

5.7

-0.00

-16172

-129084

-12589

226871

-5933

1250

-2300

153933

94537

101967 86140

2435

46049

554413

11100

8907

-11100

-8907

-5072

-8927

111250

26425

150000

29000

12589

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.5in">12.</td> <td style="text-align: left">Convertible Promissory Note</td></tr> </table>    On June 24, 2014, the Company entered into a securities purchase agreement with Typenex Co-Investment, LLC, a Utah limited liability company. Under this agreement, the Company has issued a secured convertible promissory note in the original principal amount of $1,105,000, deliverable in eleven tranches (the “Typenex Note”). On the closing date, Typenex delivered the initial cash purchase price of $150,000, plus any interest, costs, fees or charges accrued under the Typenex Note, including the original issue discount of $20,000. The outstanding principal and accrued and unpaid interest on the Typenex Note is convertible at any time into shares of common stock at a conversion price of $1.00, subject to adjustment as described below (the “Lender Conversion Price”). As of June 24, 2014, the Company evaluated the Beneficial Conversion Feature under this note and determined as of June 24, 2014, there was no beneficial conversion feature as the Lender Conversion Price exceeded the fair market value of the Company’s common stock.    As of November 30, 2014, the company has received net proceeds of $135,000 related to this convertible promissory note, representing $150,000 less financing costs of $15,000. During the nine months ended November 30, 2014 the Company has recorded interest expense of $7,725, and amortization expense of $554,413 related to the amortization of the original issue discount and the full-value of the warrant discussed below ($552,500).    Each subsequent tranche will be in the amount of $85,000, plus any interest, costs, fees or charges accrued thereon under the terms of the Typenex Note, including the original issuer discount of $8,500. Each tranche will be accompanied by its own secured investor note (the “Investor Notes”). The Company has agreed to pay $5,000 to cover Typenex’s legal fees, accounting costs, due diligence, monitoring and other transaction costs in connection with the purchase and sale of the Typenex Note. All loans received bear an interest rate of 10% per annum. The loan is due 23 months after the initial cash purchase price is delivered to the Company. Typenex has pledged a 40% membership interest in Typenex Medical, LLC to secure its obligations under all of the Typenex Notes.    A warrant to purchase shares of the Company has been issued to Typenex as of June 24, 2014. This warrant grants Typenex the ability to purchase a number of fully paid and non-assessable shares of the Company’s stock, par value $0.001, equal to $552,500 divided by the market price. This warrant is issued pursuant to the terms of the securities purchase agreement as described above.    Provided there is an outstanding balance, the Company will pay an installment amount equal to $61,388.89 plus any accrued and unpaid interest on the installment due date, which is six months after the initial loan disbursement. This installment amount is the maximum that must be paid on any given installment due date, and is limited by the amounts owed. This amount can be converted at the lesser of either the lender conversion price or at 70% of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion. Should the average trading price be less than $0.35 during any such period, then the conversion factor will be reduced to 65% for all future conversion, additionally the conversion price will be reduced by 5% if the Company’s common stock is not available for DWAC. Should the Company decide to prepay this amount, there is a prepayment premium equal to 125% of the outstanding balance of the Typenex Note. Should the prepayment premium not be paid within 2 days of the prepayment notice, the Company forfeits its right to prepay the Typenex Note.    Under this agreement, Typenex has the right at any time after the purchase price date until the outstanding balance has been paid in full to convert any or all of the outstanding balance into shares of the Company’s common stock under the following formula: the number of shares issued equals the amount being converted divided by $1. These shares must be delivered to Typenex within three trading days of the conversion notice being given to the Company. Should any shares be sold to Typenex or any third party at a value that is less than the effective lender conversion price, then the lender conversion price will be reduced to equal such lower issuance price. The effective lender conversion price will also be adjusted as needed upon any forward or reverse split of the Company’s shares. Should the Company fail to deliver the shares in a timely manner, a late fee of the greater of $500 per day and 2% of the applicable lender conversion share value rounded to the nearest multiple of $100 will be assed for each day after the third that the Company is late (though not exceeding 200% of the applicable lender conversion share value.    In the event of a default, the Typenex Note may be accelerated by Typenex by providing written notice to the Company. The outstanding balance is immediately due and payable at the greater of the outstanding balance divided by the installment conversion price, or the default effect, which is calculated by multiplying the conversion eligible outstanding balance by 15% for each major default or 5% for each minor default and then adding the resulting product to the outstanding balance as of the date of default. In addition, an interest rate of the lesser of 22% per annum (or the maximum rate permitted under law) will be applied to the outstanding balance. Typenex is prohibited from owning more than 4.99% of the Company’s outstanding shares, unless the market capitalization of the Company’s common stock is less than $10,000,000, in which case Typenex is prohibited from owning more than 9.99% of the Company’s outstanding shares.    On a date that is 23 trading days from each date that the Company delivers conversion shares to Typenex, there is a true-up date in which the Company will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.   Notice of Default – on January 9, 2015, the Company received a Notice of Default from Typenex under the Convertible Promissory Note described in Note 12 above. In the letter, the noteholder described two major defaults where the Company failed to meet its obligations under the Typenex Note. The first default was triggered on December 16, 2014 related to a request from the noteholder to increase the number of shares reserved for issuance under the Typenex Note on the books of the Company’s transfer agent. The second default was triggered on December 27, 2014, when the Company failed to make its first installment payment of $61,888.89 according to the terms of the Typenex Note. Each default triggered a penalty of 115% of the then outstanding principal and accrued and unpaid interest and triggers the interest rate to 22%. As of January 9, 2015, the outstanding principal, accrued interest and accrued penalties on the Typenex Note was $239,483.61. On January 23, 2015, the Company satisfied its first default by instructing its transfer agent to reserve a total of 50,925,000 shares of common stock covering the potential conversion of the original principal value of the Typenex Note ($1,100,000) plus common shares issuable upon the exercise of warrants underlying the Typenex Note. On February 12, 2015, the Company received a notice from Typenex waiving the penalties on the December 16, 2014 default and waived $26,755.16 of penalties imposed on December 16, 2014. Under the terms of the Typenex Note, the Lenders Conversion Price will reset to 60% of the average of the three lowest closing bid prices of the Company’s common stock in the 20 days prior to conversion. As of December 16, 2014, the Company has re-evaluated the beneficial conversion feature under the Typenex Note and has recorded a liability for the beneficial conversion feature totaling $230,392. This discount will be amortized over the remaining life of the Typenex Note.    On February 3, 2015, the Company exercised its borrower offset right under the Typenex Note.  Through this offset right, the Company is entitled to deduct and offset any amount owing by Typenex under the initial securities purchase agreement dated June 24, 2014 from any amount owed by the Company under the note.  The combined balance of the secured investor notes and the investor notes as of the January 28, 2015 offset date was $890,800.  In addition, the note balance prior to the offset included $85,000 of unearned original issue discounts.    In conjunction with the Company’s exercise of its offset right, the Company and Typenex each hereby acknowledge that the secured investor notes and the investor notes were offset against the Company balances owed under the note as of the offset date, and as a result thereof, each of the secured investor notes and the investor notes is deemed to have been paid in full and are now cancelled and terminated and the Company balance owed under the note has been reduced to $218,028.47 as of the offset date.  Additionally, the Company specifically acknowledges that Typenex has no further obligations under any of the secured investor notes and investor notes.    Further, the Company acknowledges that the investor pledge agreement, dated June 24, 2014, and all security interests granted thereunder with respect to the collateral (as defined in the investor pledge agreement) have terminated and all such security interests shall be deemed released.    Notice of Conversion – Between February 28, 2016 and August 31, 2016, the Company has received no further conversion notices from its noteholder on the Typenex Note to convert principal on the Typenex Note into shares of the Company’s Common Stock at a market price as defined by the Typenex Note. <table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.5in">13.</td> <td style="text-align: left">Securities Purchase Agreement</td></tr> </table>    On September 17, 2014, the Company entered into a securities purchase agreement with YP Holdings, LLC.  YP Holdings, LLC has no material relationship with the Company other than with respect to this agreement.    Under this agreement, the purchasers will be purchasing units of one common share and two warrants to purchase common shares for $0.09 per unit, for a total of $600,000.  The common shares have a par value of $0.001 per share.  The warrants are exercisable for five years from the date of issuance and shall have an initial exercise price equal to $0.20.  As a result of this agreement, the Company issued 667 (6,666,667 pre-split) common shares and 1,333 (13,333,333 pre-split) warrants to the purchasers. On August 29, 2014 and September 17, 2014, the Company received gross proceeds of $100,000 and $500,000, respectively and has recorded financing fees of $18,000 and $52,000, related to this agreement.    The warrants can be exercised by paying the price for shares as stipulated by the warrant, or through cashless exercise, through which the purchaser will be issued a number of shares equal to the number of warrant shares applied to the subject exercise multiplied by the current market price on the date of conversion minus the exercise price on that date.  This total is then divided by the current market price on the date of conversion.  The cashless exercise may only be exercised after six months have passed from the original issuance of the warrants.    The purchaser has waived the clause prohibiting conversion of warrants into common shares if that would result in the purchaser owning in excess of 4.99% of the outstanding shares.  A second clause prohibits the conversion of warrants if the purchaser owns in excess of 9.99% of the outstanding common shares.  This clause can be waived by the purchaser providing notice of waiver.    The Company has agreed to pay a flat $20,000 to YP Holdings, LLC to reimburse them for the fees and expenses incurred by it in connection with its due diligence review of the Company and the preparation, negotiation, executive, delivery and performance of the agreement.    The two parties also entered into a registration rights agreement.  Under this agreement, the Company will prepare and file a registration statement on Form S-1 in order to register all shares issued under the securities purchase agreement.  The Company will keep the registration statement continuously effective for a period of two years following the effective date of the registration statement.  The Company will pay all reasonable fees and expenses incurred with respect to this agreement.  Unless previously agreed to in writing, the Company may not register any shares other than those intended to be sold under this agreement.    Should the Company fail to comply with the registration rights agreement, the Company agrees to pay liquidated damages to YP Holdings, LLC equal to 3% of the purchase price of the common shares paid by the purchaser for the first 30 day period, and 2% of such purchase price for each subsequent 30 day period.  These payments are payable upon demand in cash.    Pursuant to the registration rights agreement, the Company agreed to several lock-up agreements between itself and four shareholders of the Company: Phoenix Bio Pharmaceuticals Corporation, Ronald Lusk, Lewis Humer, and Caduceus Industries LLC.  Under these agreements, each shareholder has agreed that they will not offer, pledge, sell, contract to sell, grant any options for sale or transfer, distribute or dispose of, directly or indirectly, any shares of the Company for a 90 day period following the date that the registration statement is declared effective.    Additionally, on September 16, 2014, the Company issued warrants to purchase 53 (533,333 pre-split) common shares to consultants for services rendered. The warrants expire five years from the date of issuance and are exercisable for $0.20 per share. The Company has valued these warrants using the Black Scholes option pricing model and has recorded expense related to the issuance of these warrants totaling $104,578 during the quarter ended May 31, 2014.

<table cellspacing="0" cellpadding="0" style="margin-bottom: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.5in">14.</td> <td style="text-align: left">Subsequent Events</td></tr> </table>    On September 15, 2016, Typenex Co-Investment, LLC exercised part of their warrant and were issued 2,822 shares of common stock.    On September 21, 2016, the registrant dismissed Fruci & Associates II, PLLC as their registered independent public accountant. On September 21, 2016, the Company’s Board of Directors approved the engagement of BMKR, LLP to provide auditing services on a prospective basis, and to perform a full audit of the Company’s books and records for the years ended February 29, 2016, February 28, 2017 and February 28, 2018.    On March 8, 2017, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from MediJane Holdings, Inc. to Stem Bioscience, Inc.    On May 31, 2018, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from Stem Bioscience, Inc. to Phoenix Life Science International Limited.    Pursuant to the Agreement and Plan of Merger, dated as of September 18, 2018 as (The “Merger Plan” by and between Phoenix Life Sciences International Limited, a Nevada Corporation (the “Company”) and Phoenix Life Sciences International Limited, a Canadian Corporation (“PLSI CA”), the Company completed its merger with PLSI CA, with the Company as the surviving entity.    On September 18, 2018, the Company’s Board of Directors announced the finalized consolidation activities of Phoenix Life Sciences International Limited with Stem Biosciences, Inc., Blue Dragon Ventures, and the MediJane Brand, and that the Company’s common stock would trade publicly under the symbol MJMD.    On September 21, 2018, the Company announced it had obtained consent from the holder, Phoenix Bio Pharmaceuticals Corporation for the cancellation of 2,000,000 Preferred Series B shares in the Company in connection with the restructure of the Company and merger with Phoenix Life Sciences International Limited, a Canadian Corporation.    On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director.    On or about June 24, 2014, the Company entered into a Convertible Promissory Note with a face value of $1,105,000 (the “Note”) by and between the Company and Typenex Co-Investment, LLC (“Typenex”). On or about April 19, 2018, the Phoenix Life Sciences International Ltd, a Canadian Corporation (“PLSI CA”) acquired the entirety of the Notes outstanding principal and interest balance from Typenex. Upon the completion of the merger, that Note was conveyed to the Company.    On September 22, 2018, the Company’s Board of Directors resolved to deem the acquired Notes principal balance satisfied, and to terminate the Note and any and all rights and obligations arising thereunder, including without limitation the cancellation of all Warrants issued to Typenex under the Note.    On September 24, 2018, the Company issued 30,502,375 shares of common stock bearing the restricted legend without registration (the “Issued Shares”). Of these, 29,802,375 shares were issued in reliance on Rule 802 under the Securities Act in a 1:1 share exchange related to the merger of PLSI CA and the company as described above, and 700,000 shares were issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. All of the Issued Shares were issued in private transactions, and the company received no proceeds from the Issued Shares. The Issued Shares, in conjunction with the 47,571 shares of common stock previously issued by the Company, brings the current issued and outstanding share count to 30,549,946.    On October 3, 2018, the following persons were appointed to the Board of the Company, Stephen Cornford, Martin Tindall as Chief Executive Officer, Janelle Marsden as Managing Director and Geoffrey Boynton as Chief Financial Officer. Lewis “Spike” Humer stepped down from his executive role but remains a Director.    On October 3, 2018, the Company agreed to issue 48,000 shares of restricted common stock to KHAOS Media Group as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act for services previously rendered and invoiced between March and December 2014.    On November 2, 2018, FINRA confirmed the name change and change of symbol to “PLSI”    On November 9, 2018, the Company announced that 2,000,000 Series C Preferred Stock had been cancelled and all convertible debt had been retired. There was no outstanding preferred stock on issue as at this day.    On December 4, 2018, the Company issued 229,600 common shares as part of settlement agreements.    On December 17, 2018, the Company issued 675,028 common shares which included 191,668 common shares as part of settlement agreements and 483,360 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act    On January 11, 2019, the Company issued 500,600 common shares to YP Holding, LLC. as part of a settlement agreement.    On January 15, 2019 the Company issued 54,580 common shares which included 53,500 common shares as part of settlement agreements and 1,080 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act    On February 20, 2019 the Board of the Company appointed Michael Gobel, who has long and distinguished career in corporate finance in Australia, as a non-executive Director    On February 26, 2019 the Company issued 315,928 common share which included 5,460 common shares as part of settlement agreements, 126,750 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act and 183,718 for cash consideration.    On April 2, 2019 the Company issued 151,216 common share for cash consideration.    Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) commenced the consolidation of business in 2018. During that time, affiliates of the Company provided certain working capital and covering of costs related to the consolidation. Subsequently the Company has entered into subscription agreements with certain affiliates and key non-affiliate investors to provide a total of approximately USD $2.1million of financing. Shares of common stock issued for this total financing represent approximately 800,000. The key non-affiliate investor who had previously entered into a subscription agreement to purchase USD $20 million of shares at $10 per share with Phoenix Life Sciences International Limited Canada has entered into an agreement to exchange the subscription for warrants to purchase Company common stock at a price of $10, with the purchases to be completed by December 31, 2019.    Further, as part of the merger and consolidation, Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) entered into settlement agreements with former investors, employees and contractors whereby their debt, shares held in entities subject of the consolidation, or outstanding amounts were settled in exchange for a full release of claims and the Company issuing approximately eight (8) million shares and the assumption of approximately $2 million of settlements payable. The purpose of the consolidation, in addition to providing the deemed necessary relationships and contracts for the Company to execute on its strategy, was to settle any potential claim or liability to ensure that the Company was not subject to any claims by former investors, employees and contractors.

2000000

One for 10,000

18800000

2820000

1200000

1105000

85000

890800

1100000

0.10

0.08

0.10

0.02

1.00

1200000

0.12

0.22

20000000

0.02

0.20

2500

1500 16000 1250 10000 64000 120000 P4M

258122

85000

10029

27000

81000

30421

42392

2687

15900 10525

0.0001

100

1.00

0.35

0.001

0.09

Series A preferred shares do not have any voting rights.

500 votes for each preferred share owned.

0.10 0.10

2400

4400

2000

995600 998000 2000000 2000000

20000

8500

85000

11 P23M 0.40

552500

P20D 0.70 0.65 0.60 0.05 1.25 500 0.02 2.00 0.15 0.05 0.0999 0.0499 0.0999 0.0499 0.14 10000000 P23D

239484

218028

50925000

26755 135000

15000

7725

5000

20000

1 2

P5Y

600000

500000

100000

52000

18000

533333

0.03 0.02 6666667 13333333

667

1333

151216

183718

30502375

800000

2036-12-31

2030-01-01

7500

-1250

19000

2400

600000 5 0.75

750000

1000000 0.10

61889

1.15

104578

P4Y Smaller Reporting Company

7500

49531

162305

-19852

-43389

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif">2.</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Summary of Significant Accounting Policies</td></tr></table>   Basis of Presentation – The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.  The Company’s fiscal year end is February 28 or 29.   Basis of Consolidation – The consolidated financial statements include the accounts of Phoenix Life Sciences International Limited and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   On March 17, 2014, MediHoldings, Inc (“MediHoldings”), a Colorado corporation, was formed as a wholly owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly owned subsidiary of the Company. These companies have not traded and are inactive.   Stock Split – on October 21, 2015 the Company’s Board of Directors declared a One for 10,000 reverse stock split on its common stock as of a record date of October 22, 2015. The effect of the stock split decreased the number of shares of common stock outstanding from 501,242,594 to 50,125. All common share and per common share data in these financial statements and related notes here to have been retroactively adjusted to account for the effect of the stock split for all periods presented. The total number of authorized common shares on the par value thereof was not changed by the split.   Use of Estimates – The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.    A significant item that requires management’s estimates and assumptions is the valuation of intangible assets, valuation allowances for income tax, valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.   Cash and cash equivalents – The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. At August 31, 2016 and February 28, 2016, the Company did not hold any cash equivalents.   Accounts receivable – Accounts receivable consists of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts receivable are carried at the original invoice amount less a reserve for doubtful receivables based on a review of all outstanding amounts on a monthly basis.   Basic and Diluted Net Loss per Share – The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. At February 28, 2016 and August 31, 2016, the Company had no outstanding stock options. At August 31, 2016 and 2015, the Company had did not have potentially dilutive shares outstanding.   Financial Instruments – Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:   Level 1 – Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2 – Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3 – Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.    Derivative Financial Instruments – The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks.   The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.   Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.   The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.   Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.   Comprehensive Loss – ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at August 31, 2016 and 2015, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.   Stock-based Compensation – The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Based Compensation and ASC 505-50 - Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.   We account for share-based payments granted to non-employees in accordance with ASC Topic 505, “Equity Based Payments to Non-Employees.” The Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.  If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.   The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:    Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.     Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.    Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.   Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding.  We estimated the expected term of stock options by using the simplified method.  For warrants, the expected term represents the actual term of the warrant.   Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.   Revenue Recognition – The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin Topic 13 when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection is probable. The Company assesses whether the fee is fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. Up-front engagement fees are recorded as deferred revenue and amortized to income on a straight-line basis over the term of the agreement, although the fee is due and payable at the time the agreement is signed or upon annual renewal. Payments related to substantive, performance-based milestones in an agreement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreement when they represent the culmination of the earnings process.   The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a fee is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates.   Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations.   Recent Accounting Pronouncements – The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.    Reclassifications - Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

Basis of Presentation – The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars.  The Company’s fiscal year end is February 28 or 29.

Basis of Consolidation – The consolidated financial statements include the accounts of Phoenix Life Sciences International Limited and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   On March 17, 2014, MediHoldings, Inc (“MediHoldings”), a Colorado corporation, was formed as a wholly owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly owned subsidiary of the Company. These companies have not traded and are inactive.

Use of Estimates – The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.    A significant item that requires management’s estimates and assumptions is the valuation of intangible assets, valuation allowances for income tax, valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.

Cash and cash equivalents – The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. At August 31, 2016 and February 28, 2016, the Company did not hold any cash equivalents.

Accounts receivable – Accounts receivable consists of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts receivable are carried at the original invoice amount less a reserve for doubtful receivables based on a review of all outstanding amounts on a monthly basis.

Basic and Diluted Net Loss per Share – The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. At February 28, 2016 and August 31, 2016, the Company had no outstanding stock options. At August 31, 2016 and 2015, the Company had did not have potentially dilutive shares outstanding.

Financial Instruments – Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:   Level 1 – Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2 – Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3 – Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

Derivative Financial Instruments – The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks.   The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.   Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.   The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method.   Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.

Comprehensive Loss – ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at August 31, 2016 and 2015, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

Stock-based Compensation – The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Based Compensation and ASC 505-50 - Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.   We account for share-based payments granted to non-employees in accordance with ASC Topic 505, “Equity Based Payments to Non-Employees.” The Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.  If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete.   The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:    Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.     Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.    Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.   Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding.  We estimated the expected term of stock options by using the simplified method.  For warrants, the expected term represents the actual term of the warrant.   Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

Revenue Recognition – The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin Topic 13 when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection is probable. The Company assesses whether the fee is fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. Up-front engagement fees are recorded as deferred revenue and amortized to income on a straight-line basis over the term of the agreement, although the fee is due and payable at the time the agreement is signed or upon annual renewal. Payments related to substantive, performance-based milestones in an agreement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreement when they represent the culmination of the earnings process.   The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a fee is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates.

Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations.

Recent Accounting Pronouncements – The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Reclassifications - Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

Stock Split – on October 21, 2015 the Company’s Board of Directors declared a One for 10,000 reverse stock split on its common stock as of a record date of October 22, 2015. The effect of the stock split decreased the number of shares of common stock outstanding from 501,242,594 to 50,125. All common share and per common share data in these financial statements and related notes here to have been retroactively adjusted to account for the effect of the stock split for all periods presented. The total number of authorized common shares on the par value thereof was not changed by the split.

2100000

5460

315928

54580

53500

500600

191668

675028

229600

8000000

29802375 1:1

126750

1080

483360

48000

700000

2000000 2000000 20000000

10.00

2000000

47571

2822

EX-101.SCH 7 plsi-20160831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations - Unaudited link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature of Operations and Continuance of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Variable Interest Entity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - CV Sciences, Inc. FKA CannaVest Corp. link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsidiary Companies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Convertible Promissory Note link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Securities Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Nature of Operations and Continuance of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - CV Sciences, Inc. FKA CannaVest Corp. (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Convertible Promissory Note (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Securities Purchase Agreement (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 plsi-20160831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 plsi-20160831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 plsi-20160831_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series B Preferred Stock [Member] Series C Preferred Stock [Member] Related Party [Axis] Phoenix Bio Pharm [Member] Finite-Lived Intangible Assets by Major Class [Axis] Additional License Agreement [Member] Range [Axis] Maximum [Member] Minimum [Member] Class of Warrant or Right [Axis] Warrant [Member] Short-term Debt, Type [Axis] Convertible Promissory Notes [Member] Kronos [Member] Phoenix Pharms [Member] Mr. Humer - CEO And Director [Member] Agreement [Axis] New Product Development Agreement [Member] Series A Preferred Stock [Member] Series D Preferred Stock [Member] YP Holding, LLC [Member] Securities Agreement [Member] Long-term Debt, Type [Axis] Typenex Note [Member] Debt Instrument, Redemption, Period [Axis] Tranche [Member] Debt Conversion Description [Axis] Notice 1 [Member] Equity Components [Axis] Common Stock [Member] Warrant [Member] Capital Units by Class [Axis] Purchasing Unit [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Settlement Agreements [Member] KHAOS Media Group [Member] Award Type [Axis] Restricted Common Stock [Member] Sale of Stock [Axis] Private Placement [Member] Business Acquisition [Axis] Phoenix Life Sciences International Limited [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Subscription Agreements [Member] Non Affiliate Investor [Member] Mr. Russell Stone [Member] Consultants [Member] Typenex Co-Investment, LLC [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Trading Symbol Amendment Flag Current Fiscal Year End Date Entity's Reporting Status Current Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Cash Notes receivable, related party Total Current Assets Total Assets LIABILITIES Current Liabilities Accounts payable and accrued liabilities Due to related parties Current Liabilities Convertible notes payable, net Derivative liability Total Liabilities STOCKHOLDERS' DEFICIT Common Stock Authorized: 990,000,000 common shares, par value of $0.001 per share Issued and outstanding: 28,245 and 25,845 common shares, respectively Issued and outstanding Preferred shares Additional paid-in capital Accumulated deficit during the development stage Total Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Income Statement [Abstract] Revenues Cost of Sales Gross Profit Operating expenses Product development expense Sales and marketing expenses Operations expense General and administrative Professional fees Lease operating expenses Total operating expenses Loss before other expenses Other income (expense) Interest Income Interest Expense Debt Issue costs Discount Amortization Gain (loss) on derivative liability Total other income (expense) Net profit (loss) Basic and diluted loss per common share: Income (loss) from continuing operations (in dollars per share) Basic and diluted loss per common share (in dollars per share) Weighted average shares outstanding - basic and diluted (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Non-cash amortization of discount on convertible notes payable Non-cash interest expense on convertible notes payable Non-cash stock option compensation Non-cash loss (gain) on derivative liability Changes in operating assets and liabilities: Accounts receivable Deposit Inventory Accounts payable and accruals Net Cash provided by (used for) operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Related party notes receivable Net Cash provided by (used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from notes payable Due to related parties Net Cash Provided By Financing Activities Increase (Decrease) in Cash - continuing operations Cash - Beginning of Period - continuing operations Cash - End of Period - continuing operations Supplemental disclosures Interest paid Income tax paid Non-cash issuance of stock for consulting agreements Non-cash issuance of stock for distribution agreement Non-cash issuance of stock for conversion of debt Organization, Consolidation and Presentation of Financial Statements [Abstract] Nature of Operations and Continuance of Business Accounting Policies [Abstract] Summary of Significant Accounting Policies Variable Interest Entity Variable Interest Entity Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Income Tax Disclosure [Abstract] Income Taxes Debt Disclosure [Abstract] CV Sciences, Inc. FKA CannaVest Corp. Subsidiary Companies Subsidiary Companies Related Party Transactions [Abstract] Related Party Transactions Common Stock Common Stock Number of stock issued, cash consideration Preferred Stock Common Stock Options Common Stock Options Debt term Convertible Promissory Note Number of stock issued, cash consideration Securities Purchase Agreement Subsequent Events [Abstract] Subsequent Events Basis of Presentation Basis of Consolidation Stock Split Use of Estimates Cash and cash equivalents Accounts receivable Basic and Diluted Net Loss per Share Financial Instruments Derivative Financial Instruments Comprehensive Loss Stock-based Compensation Revenue Recognition Shipping and Handling Costs Recent Accounting Pronouncements Reclassifications Common shares issued Common shares exchanged for Series B preferred shares EX-101.PRE 11 plsi-20160831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Aug. 31, 2016	Feb. 28, 2019
Document And Entity Information
Entity Registrant Name	Phoenix Life Sciences International Limited.
Entity Central Index Key	0001493212
Document Type	10-Q
Document Period End Date	Aug. 31, 2016
Trading Symbol	PLSI
Amendment Flag	false
Current Fiscal Year End Date	--02-28
Entity's Reporting Status Current	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		32,584,582
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($)	Aug. 31, 2016	Feb. 29, 2016
ASSETS
Cash	$ 2,519	$ 7,591
Notes receivable, related party	238,252	249,352
Total Current Assets	240,771	256,943
Total Assets	240,771	256,943
Current Liabilities
Accounts payable and accrued liabilities	500,053	512,642
Due to related parties	267,219	267,219
Current Liabilities	767,272	779,861
Convertible notes payable, net	297,708	193,306
Derivative liability	243,579	397,512
Total Liabilities	1,308,559	1,370,679
STOCKHOLDERS' DEFICIT
Common Stock Authorized: 990,000,000 common shares, par value of $0.001 per share Issued and outstanding: 28,245 and 25,845 common shares, respectively	28	26
Additional paid-in capital	17,704,975	17,704,977
Accumulated deficit during the development stage	(18,773,091)	(18,819,039)
Total Stockholders' Equity (Deficit)	(1,067,788)	(1,113,736)
Total Liabilities and Stockholders' Equity	240,771	256,943
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares	200	200
Series C Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares	$ 100	$ 100

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Aug. 31, 2016	Feb. 29, 2016
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	990,000,000	990,000,000
Common stock, issued	28,245	25,845
Common stock, outstanding	28,245	25,845
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, issued	2,000,000	2,000,000
Preferred stock, outstanding	2,000,000	2,000,000
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001
Preferred stock, issued	995,600	998,000
Preferred stock, outstanding	995,600	998,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - Unaudited - USD ($)	3 Months Ended		6 Months Ended
	Aug. 31, 2016	Aug. 31, 2015	Aug. 31, 2016	Aug. 31, 2015
Income Statement [Abstract]
Revenues		$ 15,975		$ 18,410
Cost of Sales		5,035		5,933
Gross Profit		10,940		12,477
Operating expenses
Product development expense		70,000		100,000
Sales and marketing expenses		6,306		14,345
Operations expense				1,745
General and administrative	$ 1,273	15,080	$ 3,253	30,876
Professional fees		79,437	330	217,712
Lease operating expenses				7,500
Total operating expenses	1,273	170,823	3,583	372,178
Loss before other expenses	(1,273)	(159,883)	(3,583)	(359,701)
Other income (expense)
Interest Income		980		2,093
Interest Expense	(16,271)	(41,024)	(101,967)	(86,140)
Debt Issue costs		(7,830)		(7,830)
Discount Amortization			(2,435)	(46,049)
Gain (loss) on derivative liability	178,576	28,022	153,933	94,537
Total other income (expense)	162,305	(19,852)	49,531	(43,389)
Net profit (loss)	$ 161,031	$ (179,735)	$ 45,948	$ (403,090)
Basic and diluted loss per common share:
Income (loss) from continuing operations (in dollars per share)	$ 5.7	$ (0.00)	$ 1.63	$ (0.00)
Basic and diluted loss per common share (in dollars per share)	$ 5.7	$ 0	$ 1.63	$ 0
Weighted average shares outstanding - basic and diluted (in shares)	28,245	258,030,222	28,206	364,290,048

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Aug. 31, 2016	Aug. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ 45,948	$ (403,090)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash amortization of discount on convertible notes payable	2,435	46,049
Non-cash interest expense on convertible notes payable	101,967	86,140
Non-cash stock option compensation
Non-cash loss (gain) on derivative liability	(153,933)	(94,537)
Changes in operating assets and liabilities:
Accounts receivable		2,300
Deposit		1,250
Inventory		5,933
Accounts payable and accruals	(12,589)	226,871
Net Cash provided by (used for) operating activities	(16,172)	(129,084)
CASH FLOWS FROM INVESTING ACTIVITIES:
Related party notes receivable	11,100	8,907
Net Cash provided by (used in) Investing Activities	11,100	8,907
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable
Due to related parties		111,250
Net Cash Provided By Financing Activities		111,250
Increase (Decrease) in Cash - continuing operations	(5,072)	(8,927)
Cash - Beginning of Period - continuing operations	7,591	9,400
Cash - End of Period - continuing operations	2,519	473
Supplemental disclosures
Interest paid
Income tax paid	12,589
Non-cash issuance of stock for consulting agreements
Non-cash issuance of stock for distribution agreement
Non-cash issuance of stock for conversion of debt		$ 29,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations and Continuance of Business

6 Months Ended

Aug. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations and Continuance of Business

Nature of Operations and Continuance of Business

On February 27, 2014, after the change of control, the Company became a sales and distribution company focused on cannabinoid infused products for the treatment of medical conditions.

Going Concern

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Aug. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Level 1 – Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Derivative Financial Instruments – The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks.

Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.

Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Variable Interest Entity

6 Months Ended

Aug. 31, 2016

Variable Interest Entity

Variable Interest Entity

Variable Interest Entity

	-	The reporting entity, its related parties, or both participated significantly in the design or redesign of the legal entity;
	-	The legal entity is designed so that substantially all of its activities involve or are conducted on behalf of the reporting entity and its related parties;
	-	The reporting entity and its related parties provide more than half of the total of the equity, subordinated debt, and other forms of subordinated financial support to the legal entity; or
	-	The activities of the legal entity are primarily related to the securitizations or other forms of asset-backed financings or single-lessee leasing arrangements.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Aug. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intagible Assets

XML 21 R10.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Aug. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

XML 22 R11.htm IDEA: XBRL DOCUMENT

CV Sciences, Inc. FKA CannaVest Corp.

6 Months Ended

Aug. 31, 2016

Debt Disclosure [Abstract]

CV Sciences, Inc. FKA CannaVest Corp.

CV Sciences, Inc. FKA CannaVest Corp.

Warrant Agreement

It was determined that the remaining inventory should be written off as at February 29, 2016.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Subsidiary Companies

6 Months Ended

Aug. 31, 2016

Subsidiary Companies

Subsidiary Companies

Subsidiary Companies

On March 17, 2014, MediHoldings, Inc. (“MediHoldings”), a Colorado corporation, was formed as a wholly-owned subsidiary of the Company.

On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly-owned subsidiary of the Company.

Both these subsidiaries as at August 31, 2016 had not traded and were inactive.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Aug. 31, 2016

Related Party Transactions

Related Party Transactions

Martin Tindall

Kronos International Investments Ltd. (“Kronos”)

Phoenix Pharms Capital Corporation (“Phoenix Pharms”)

Russell Stone: Mr. Russell Stone, the Company’s Chief Operating Officer, holds approximately 14% of the outstanding common shares of Phoenix Pharms Capital Corporation indirectly through a trust.

Lewis “Spike” Humer:

XML 25 R14.htm IDEA: XBRL DOCUMENT

Common Stock

6 Months Ended

Aug. 31, 2016

Common Stock

Common Stock

Common Stock

The Company has authorized 990,000,000 shares of its common stock, $0.001 par value. On February 29, 2016 there were 25,845 shares of common stock on issue.

On March 4, 2016, YP Holdings LLC converted 2,400 series C preferred stock to 2,400 shares of common stock.

As at August 31, 2016, there were 28,245 shares of common stock issued and outstanding.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Preferred Stock

6 Months Ended

Aug. 31, 2016

Number of stock issued, cash consideration

Preferred Stock

10.

Preferred Stock

Series A Preferred Stock:

Series B Preferred Stock:

Series C Preferred Stock:

Series D Preferred Stock

On March 4, 2016, YP Holdings, LLC converted 2,400 series C preferred stock to 2,400 shares of common stock.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Common Stock Options

6 Months Ended

Aug. 31, 2016

Common Stock Options

Common Stock Options

11.

Common Stock Options

As at August 31, 2016 and February 29, 2016 there were no common stock options on issue.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Convertible Promissory Note

6 Months Ended

Aug. 31, 2016

Debt term

Convertible Promissory Note

12.

Convertible Promissory Note

XML 29 R18.htm IDEA: XBRL DOCUMENT

Securities Purchase Agreement

6 Months Ended

Aug. 31, 2016

Securities Purchase Agreement Abstract

Securities Purchase Agreement

13.

Securities Purchase Agreement

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Aug. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

14.

Subsequent Events

On September 15, 2016, Typenex Co-Investment, LLC exercised part of their warrant and were issued 2,822 shares of common stock.

On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director.

On November 2, 2018, FINRA confirmed the name change and change of symbol to “PLSI”

On December 4, 2018, the Company issued 229,600 common shares as part of settlement agreements.

On January 11, 2019, the Company issued 500,600 common shares to YP Holding, LLC. as part of a settlement agreement.

On February 20, 2019 the Board of the Company appointed Michael Gobel, who has long and distinguished career in corporate finance in Australia, as a non-executive Director

On February 26, 2019 the Company issued 315,928 common share which included 5,460 common shares as part of settlement agreements, 126,750 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act and 183,718 for cash consideration.

On April 2, 2019 the Company issued 151,216 common share for cash consideration.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Aug. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation – The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28 or 29.
Basis of Consolidation	Basis of Consolidation – The consolidated financial statements include the accounts of Phoenix Life Sciences International Limited and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. On March 17, 2014, MediHoldings, Inc (“MediHoldings”), a Colorado corporation, was formed as a wholly owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly owned subsidiary of the Company. These companies have not traded and are inactive.
Stock Split	Stock Split – on October 21, 2015 the Company’s Board of Directors declared a One for 10,000 reverse stock split on its common stock as of a record date of October 22, 2015. The effect of the stock split decreased the number of shares of common stock outstanding from 501,242,594 to 50,125. All common share and per common share data in these financial statements and related notes here to have been retroactively adjusted to account for the effect of the stock split for all periods presented. The total number of authorized common shares on the par value thereof was not changed by the split.
Use of Estimates	Use of Estimates – The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. A significant item that requires management’s estimates and assumptions is the valuation of intangible assets, valuation allowances for income tax, valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.
Cash and cash equivalents	Cash and cash equivalents – The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. At August 31, 2016 and February 28, 2016, the Company did not hold any cash equivalents.
Accounts receivable	Accounts receivable – Accounts receivable consists of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts receivable are carried at the original invoice amount less a reserve for doubtful receivables based on a review of all outstanding amounts on a monthly basis.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share – The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. At February 28, 2016 and August 31, 2016, the Company had no outstanding stock options. At August 31, 2016 and 2015, the Company had did not have potentially dilutive shares outstanding.
Financial Instruments	Financial Instruments – Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 – Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 – Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 – Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Derivative Financial Instruments	Derivative Financial Instruments – The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.
Comprehensive Loss	Comprehensive Loss – ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at August 31, 2016 and 2015, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.
Stock-based Compensation	Stock-based Compensation – The Company records stock-based compensation in accordance with ASC 718, Compensation – Stock Based Compensation and ASC 505-50 - Equity-Based Payments to Non-Employees. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. We account for share-based payments granted to non-employees in accordance with ASC Topic 505, “Equity Based Payments to Non-Employees.” The Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached, or (2) the date at which the counterparty’s performance is complete. The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards. Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock. Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant. Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.
Revenue Recognition	Revenue Recognition – The Company recognizes revenue in accordance with SEC Staff Accounting Bulletin Topic 13 when persuasive evidence of an arrangement exists and delivery has occurred, provided the fee is fixed or determinable and collection is probable. The Company assesses whether the fee is fixed and determinable based on the payment terms associated with the transaction. If a fee is based upon a variable such as acceptance by the customer, the Company accounts for the fee as not being fixed and determinable. In these cases, the Company defers revenue and recognizes it when it becomes due and payable. Up-front engagement fees are recorded as deferred revenue and amortized to income on a straight-line basis over the term of the agreement, although the fee is due and payable at the time the agreement is signed or upon annual renewal. Payments related to substantive, performance-based milestones in an agreement are recognized as revenue upon the achievement of the milestones as specified in the underlying agreement when they represent the culmination of the earnings process. The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a fee is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates.
Shipping and Handling Costs	Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements – The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
Reclassifications	Reclassifications - Certain amounts in the prior period financial statements have been reclassified to conform with the current period presentation. These reclassifications had no effect on previously reported losses, total assets or stockholders equity.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Nature of Operations and Continuance of Business (Details Narrative) - shares	Nov. 04, 2015	Aug. 31, 2016	Feb. 29, 2016	Jan. 05, 2015
Common shares issued		28,245	25,845
Phoenix Bio Pharm [Member] \| Series B Preferred Stock [Member]
Common shares exchanged for Series B preferred shares	2,000,000
Additional License Agreement [Member] \| Phoenix Bio Pharm [Member]
Common shares issued				276,000,000

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - shares	Oct. 22, 2015	Aug. 31, 2016	Feb. 29, 2016	Oct. 20, 2015
Accounting Policies [Abstract]
Description of reverse stock split	One for 10,000
Common stock outstanding	50,125	28,245	25,845	501,242,594

XML 34 R23.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)	6 Months Ended
Income Taxes (Details Narrative)	Aug. 31, 2016 USD ($)
Net operating losses	$ 18,800,000
Deferred tax asset net operating loss	$ 2,820,000
Minimum [Member]
Expiration Date	Jan. 01, 2030
Maximum [Member]
Expiration Date	Dec. 31, 2036

XML 35 R24.htm IDEA: XBRL DOCUMENT

CV Sciences, Inc. FKA CannaVest Corp. (Details Narrative) - USD ($)	Jan. 06, 2015	Dec. 23, 2014
Convertible Promissory Notes [Member]
Debt amount		$ 1,200,000
Interest rate		10.00%
Conversion price per common share		$ 0.02
Raw materials inventory to be acquired		$ 1,200,000
Default interest rate		12.00%
Warrant [Member]
Number of common shares for issued warrants	20,000,000
Exercise price	$ 0.02

XML 36 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)				1 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2015	Sep. 18, 2014	Aug. 14, 2014	Jun. 30, 2015	Mar. 31, 2014	Aug. 31, 2016	Aug. 31, 2015	Feb. 29, 2016	Feb. 28, 2016
Loans made to related parties							$ 258,122
Principal payments of related party loan							111,250
Kronos [Member]
Lease term						4 years
Monthly rent expense						$ 2,500
Rent expenses								$ 7,500
(Increase) Decrease in security deposit								1,250
Advisory service fees				$ 1,250	$ 10,000			120,000
Phoenix Pharms [Member]
Interest rate		8.00%
Loans made to related parties		$ 85,000
Advances repaid of related party loan									$ 10,029
Expenses invoiced from related party									30,421
Due from related party loan						42,392
Due from related party									2,687
Principal payments of related party loan									26,425
Cash payments of related party loan									15,900
Expense offset against related party loan									$ 10,525
Phoenix Pharms [Member] \| New Product Development Agreement [Member]
Monthly agreement payment							16,000
Advisory service fees							$ 64,000
Term of the agreement							4 months
Mr. Humer - CEO And Director [Member]
Monthly agreement payment			$ 1,500
Consulting fee	$ 19,000
Due to related party						$ 27,000		$ 81,000
Mr. Russell Stone [Member]
Ownership interest of Company						14.00%

XML 37 R26.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - $ / shares	Mar. 04, 2016	Aug. 31, 2016	Feb. 29, 2016	Oct. 22, 2015	Oct. 20, 2015
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Common stock, authorized		990,000,000	990,000,000
Common stock, issued		28,245	25,845
Common stock, outstanding		28,245	25,845	50,125	501,242,594
YP Holding, LLC [Member] \| Series B Preferred Stock [Member]
Number of common shares converted	2,400
Conversion of stock shares issued	2,400

XML 38 R27.htm IDEA: XBRL DOCUMENT

Preferred Stock (Details Narrative)			6 Months Ended
Preferred Stock (Details Narrative)	Mar. 04, 2016 shares	Feb. 28, 2016 shares	Aug. 31, 2016 USD ($) Number $ / shares shares	Feb. 29, 2016 shares
Minimum common shares sold			28,245	25,845
YP Holding, LLC [Member] \| Common Stock [Member]
Number of preferred shares converted		2,000
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Conversion price per share \| $ / shares			$ 1.00
Preferred stock, voting rights			Series A preferred shares do not have any voting rights.
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Conversion price per share \| $ / shares			$ 100
Preferred stock, voting rights			500 votes for each preferred share owned.
Preferred stock, issued			2,000,000	2,000,000
Number of preferred stock, owned			2,000,000
Series B Preferred Stock [Member] \| YP Holding, LLC [Member]
Number of preferred shares converted	2,400
Conversion of stock shares issued	2,400
Series B Preferred Stock [Member] \| Phoenix Bio Pharm [Member]
Preferred stock, issued		2,000,000
Number of preferred stock, owned			2,000,000
Series C Preferred Stock [Member]
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Conversion price per share \| $ / shares			$ 1.00
Percentage of preferred stock returns			10.00%
Preferred stock, issued			995,600	998,000
Preferred stock deemed \| $			$ 600,000
Series C Preferred Stock [Member] \| YP Holding, LLC [Member]
Preferred stock, issued		1,000,000	1,000,000
Number of preferred shares converted	2,400		4,400
Number of preferred stock, owned		998,000	995,600
Conseuctive trading days \| Number			5
Percentage of stock price			75.00%
Proceeds from sale of converted common stock \| $			$ 750,000
Expected proceeds from the sale of converted common stock \| $			$ 1,000,000
Minimum common shares sold			50,000
Percentage gross cash sale income			10.00%
Conversion of stock shares issued	2,400
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Conversion price per share \| $ / shares			$ 1.00
Percentage of preferred stock returns			10.00%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Convertible Promissory Note (Details Narrative)				5 Months Ended	6 Months Ended		9 Months Ended
Convertible Promissory Note (Details Narrative)	Feb. 12, 2015 USD ($)	Jan. 09, 2015 USD ($)	Jun. 24, 2014 USD ($) Number $ / shares	Nov. 30, 2014 USD ($)	Aug. 31, 2016 USD ($)	Aug. 31, 2015 USD ($)	Nov. 30, 2014 USD ($)	Feb. 29, 2016 USD ($)	Jan. 28, 2015 USD ($) $ / shares	Jan. 23, 2015 USD ($) shares	Dec. 16, 2014 USD ($)	Sep. 17, 2014
Proceeds from notes payable
Derivative liability					243,579			$ 397,512
Non-cash amortization of discount on convertible notes payable					$ 2,435	$ 46,049
Securities Agreement [Member] \| Maximum [Member]
Ownership interest of Company												9.99%
Securities Agreement [Member] \| Minimum [Member]
Ownership interest of Company												4.99%
Securities Agreement [Member] \| Typenex Note [Member]
Debt amount			$ 1,105,000						$ 890,800
Conversion price per common share \| $ / shares			$ 1.00
Original issue discount			$ 20,000						$ 85,000
Number of tranches \| Number			11
Proceeds from notes payable				$ 150,000
Membership interest pledged			40.00%
Warrant issued fair value			$ 552,500	552,500			$ 552,500
Debt installment amount			$ 61,889
Number of consecutive trading days			20 days
Conversion price equals average closing bid price (percent)			70.00%
Share price \| $ / shares			$ 0.35						$ 0.001
Conversion price reduction due to closing bid price (percent)			65.00%
Conversion price reduction due to availability of common stock (percent)			5.00%
Prepayment premium (percent)			125.00%
Late fee for failure to deliver shares			$ 500
Late fee applicable lender conversion share value (percent)			2.00%
Maximum late fee applicable lender conversion share value (percent)			200.00%
Default interest rate			22.00%
Major default rate of conversion eligible balance (percent)			15.00%
Minor default rate of conversion eligible balance (percent)			5.00%
Number of trading days from coversion date			23 days
Outstanding debt amount									$ 218,028
Amount of penalties waived	$ 26,755
Derivative liability											$ 230,932
Proceeds from notes payable, net				135,000
Financing costs				$ 15,000
Interest expense - debt							7,725
Non-cash amortization of discount on convertible notes payable							$ 554,413
Costs payable under agreement			$ 5,000
Securities Agreement [Member] \| Typenex Note [Member] \| Notice 1 [Member]
Debt amount										$ 1,100,000
Debt installment amount		$ 61,889
Conversion price reduction due to closing bid price (percent)		60.00%
Default penalty of outstanding balance (percent)		115.00%
Outstanding debt amount		$ 239,484
Common stock reserved for conversion of debt \| shares										50,925,000
Securities Agreement [Member] \| Typenex Note [Member] \| Maximum [Member]
Ownership interest of Company			9.99%
Securities Agreement [Member] \| Typenex Note [Member] \| Minimum [Member]
Ownership interest of Company			4.99%
Market capitalization under agreement			$ 10,000,000
Securities Agreement [Member] \| Typenex Note [Member] \| Tranche [Member]
Debt amount			$ 85,000
Interest rate			10.00%
Original issue discount			$ 8,500
Debt term			23 months

XML 40 R29.htm IDEA: XBRL DOCUMENT

Securities Purchase Agreement (Details Narrative) - USD ($)							3 Months Ended
	Sep. 17, 2014	Sep. 17, 2014	Sep. 17, 2014	Sep. 17, 2014	Sep. 16, 2014	Aug. 29, 2014	May 31, 2014	Aug. 31, 2016	Feb. 29, 2016
Common stock, par value (in dollars per share)								$ 0.001	$ 0.001
Warrant [Member] \| Consultants [Member]
Warrant term					5 years
Exercise price					$ 0.20
Number of warrants issued for services					533,333
Expense related to the issuance of these warrants							$ 104,578
Securities Agreement [Member]
Proceeds from issuance of purchasing units		$ 500,000				$ 100,000
Financing fees		$ 52,000				$ 18,000
Liquidated damages first 30 days (percent)		3.00%
Liquidated damages subsequent 30 days (percent)		2.00%
Securities Agreement [Member] \| Maximum [Member]
Ownership interest of Company	9.99%	9.99%	9.99%	9.99%
Securities Agreement [Member] \| Minimum [Member]
Ownership interest of Company	4.99%	4.99%	4.99%	4.99%
Securities Agreement [Member] \| Purchasing Unit [Member]
Share price	$ 0.09	$ 0.09	$ 0.09	$ 0.09
Number of common shares per unit	1	1	1	1
Number of warrants per unit	2	2	2	2
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Warrant term	5 years
Exercise price	$ 0.20	$ 0.20	$ 0.20	$ 0.20
Proceeds from issuance of purchasing units	$ 600,000
Costs payable under agreement	$ 20,000	$ 20,000	$ 20,000	$ 20,000
Securities Agreement [Member] \| Common Stock [Member]
Pre split			6,666,667
Number of share issued			667
Securities Agreement [Member] \| Warrant [Member]
Pre split				13,333,333
Number of share issued				1,333

XML 41 R30.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)													6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 02, 2019	Feb. 26, 2019	Jan. 15, 2019	Jan. 11, 2019	Dec. 17, 2018	Dec. 04, 2018	Nov. 09, 2018	Oct. 03, 2018	Sep. 24, 2018	Sep. 21, 2018	Sep. 15, 2018	Mar. 04, 2016	Aug. 31, 2016	Feb. 29, 2016	Oct. 22, 2015	Oct. 20, 2015
Common stock outstanding (shares)													28,245	25,845	50,125	501,242,594
Phoenix Life Sciences International Limited [Member] \| Settlement Agreements [Member]
Shares issued for settlements during the period (shares)													8,000,000
Assumption of settlements payable in merger													$ 2,000,000
Phoenix Bio Pharm [Member] \| Series B Preferred Stock [Member]
Number of preferred shares cancelled (shares)										2,000,000
YP Holding, LLC [Member] \| Series B Preferred Stock [Member]
Number of preferred shares converted to common stock (shares)												2,400
YP Holding, LLC [Member] \| Series C Preferred Stock [Member]
Number of preferred shares converted to common stock (shares)												2,400	4,400
Subsequent Event [Member]
Shares issued new issues during the period (shares)	151,216
Shares issued for settlements during the period (shares)		315,928	54,580		675,028
Common stock outstanding (shares)									30,549,946
Subsequent Event [Member] \| Subscription Agreements [Member]
Shares issued new issues during the period (shares)	800,000
Shares issued new issues during the period	$ 2,100,000
Subsequent Event [Member] \| Settlement Agreements [Member]
Shares issued new issues during the period (shares)		183,718
Shares issued for settlements during the period (shares)		5,460	53,500		191,668	229,600
Stock issued for services (shares)		126,750	1,080		483,360
Subsequent Event [Member] \| Series C Preferred Stock [Member]
Number of preferred shares cancelled (shares)							2,000,000
Subsequent Event [Member] \| Restricted Common Stock [Member] \| Private Placement [Member]
Shares issued new issues during the period (shares)									30,502,375
Common stock issued (shares)									47,571
Subsequent Event [Member] \| Restricted Common Stock [Member] \| Private Placement [Member] \| Phoenix Life Sciences International Limited [Member]
Shares issued with rule 802 (shares)									29,802,375
Stockholder's equity exchange ratio description									1:1
Stock issued for services (shares)									700,000
Subsequent Event [Member] \| Typenex Co-Investment, LLC [Member] \| Warrant [Member]
Shares issued upon exercise of warrants (shares)											2,822
Subsequent Event [Member] \| KHAOS Media Group [Member] \| Restricted Common Stock [Member]
Stock issued for services (shares)								48,000
Subsequent Event [Member] \| YP Holding, LLC [Member] \| Settlement Agreements [Member]
Shares issued for settlements during the period (shares)				500,600
Subsequent Event [Member] \| Non Affiliate Investor [Member] \| Subscription Agreements [Member]
Number of share to be purchased under agreement	20,000,000
Share price	$ 10.00
Subsequent Event [Member] \| Non Affiliate Investor [Member] \| Warrant [Member] \| Subscription Agreements [Member]
Share price	$ 10.00

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %5UDDX?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 57623B?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !5=9).L!@;FN\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NMD*@JC+!;33D)"8!.(6)=X6K6FCQ*C=VY.& MK1."!^ 8^\_GSY(;[87N [Z$WF,@B_%F=&T7A?8K=B#R B#J SH5RY3H4G/7 M!ZO-)'M4=85-4=."1E%"F8@(6?B4PV1@L=4%$?SGBC9[S_#&V&&0W8 MHL..(O"2 Y/31'\:VP:N@ E&&%S\+J"9B;GZ)S9W@)V38[1S:AB&2BX@]%51?\?LMK47-QRS\F MUQ]^5V'7&[NS_]CX(B@;^'47\@M02P,$% @ 57623IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " !5=9).[PG+\6(" !T" & 'AL+W=O^Q+=SYLQX,AZRGO%745(JO;>F;L7.+Z7LMD$@BI(V1#RQCK;J MY,IX0Z1:\EL@.D[)Q9":.L!AN H:4K5^GIF]$\\S=I=UU=(3]\2]:0C_IQ>=_X>;8\HT02# M>*EH+V9S3X=R9NQ5+[Y>=GZH/:(U+:0V0=3PH$=:U]J2\N/W:-2?-#5Q/G^W M_MD$KX(Y$T&/K/Y5762Y\U/?N] KN=?RF?5?Z!A0XGMC]-_H@]8*KCU1&@6K MA?GUBKN0K!FM*%<:\C:,56O&?CB)T4B#"7@DX ]"\E]"-!*BB8!B$_S@F0GU M$Y$DSSCK/3YDJR/Z3X&VD;K,0F^:NS-G*EJA=A]YF 4/;69$' 8$GB'0A B4 M[4D 0P('[-#QOP)'%Q'! A$8063HT8P>P_08I,>&'L_HB74!+F(%"R2@0.+0 MUY: BTAA@14HL'+H&TO 1: 05EB#"FN7CRP) ()AB1242%U^9$D D(5,;T") MC"G6X(LY!PM%"TR+5@YQS X(6D([!R]PB[%NRT0YB% MO".X?%'D6K R?QPQB<&TPQ.!DS1.TB4MN-:16\HXMB,",,F""ESPR*UGO+)5 M ,S:4@EF;WA#^\ $?^O%WPF]5*[PSDZJ3F/?^ MRIBDRI7P2;E2JD^ :5'3J]33M9KSH0\."\FZL<<'TX=&_A=02P,$% @ M57623LAK7Y)0 P 8@X !@ !X;"]W;W)K[/7E?MG8^HRL^ZQ MWD;-OM;9N@LJBX@1$D=EEE?A8M:U/=6+F3G8(J_T4QTTA[+,ZG^/NC"G>4C# M<\-SOMW9MB%:S/;95O_4]M?^J79/T:67=5[JJLE-%=1Z,P\_T86T?OJWG(6F)=*%7MNTBC7NJB:'MR''^'3L/+F&W@^/[< M^Y9?,2];HI2G^Y&N[FX=)&*SU)CL4]MF\ZJZGH?]S&![ A@!V":#B9@ ? K@7$/5D7:J? M,YLM9K4Y!75?K7W6+@KZP-UDKMK&;NZZ_URVC6L]+E@RBXYM/X/DL9>PL>1: ML404Z442N?$O$ R%8%T\'\5S@L=S-)YW\6(<3[TD>DG<2:H>4=+4RP.*E$PI M3B)0$@%)O,EZ["5R3,(3)OTY160BY2/9%8U$:22DX1Z-1(8A2GG3MT1D,DX% MQVEBE":&-,*CB3]&@\ANT"B41L$U)_'X!(U/8#:QETT","4A1'HE6"(RRF(Q M4>D4I4DAC?)H4CAIL6+@'7A7=D5#">XJ!/)(WU8(&$FYD10P%T2GTB2>>"_I MA,]12 2,CL+<4Z5(XA-!'4TY)_$$$6YZE$&BU"=BR O!I?*+ANAXJMPRFB#" M;91"'Q7$)^(P=TX2*0$2)E0D5E,K"3=4*L![*J8JCYL@A2XH?$^FB+^!JB.: MJ8KC!DBA PK?CRGT-NJ6H'#5]'DFE6J""C="JB"5[\N#9CS6'4V4XB3UO1F7 M)C0E?*KRN,%2Z+ "> CTSCOJUIA*0/4P)74KDD_5$#=:"IU6^+Y/$0_%/F.8 M[L9WC.%>RZ#7BHD5P'!O9/3#[QB;V,!!+Q.^NS+$RXAG+\MW1-P[#/8F/;6^7NZ_[4TS]8LQ].=-'E6+GX#U!+ P04 M" !5=9)./0O9.6," #5" & 'AL+W=OTU;6LU%<4#KW;%X,:58U;Y'ILSXJ<7@6I&KQG#K_6-6)_MYC0;N-"]V/@I;J4 M0@V (F_1!?_$XE>[9[('1B^GJL8-KVCC,'S>N)_@>@<#9: 5KQ7N^*3MJ%0. ME+ZISK?3QO44$2;X*)0+)!\WO,.$*$^2X\_@U!UC*L-I^\/[%YV\3.: .-Y1 M\KLZB7+CIJYSPF=T)>*%=E_QD%#D.D/VW_$-$RE7)#+&D1*N_YWCE0M:#UXD M2HW>^V?5Z&?7OXFSP3EX*;\#))M+_$G$G^NV%D4V2@!,OX(X5LA M?&T?3B&@ =%+$BUIM,1;>9ZAVCU2S5@"*TNP9#'2W?:2:!(ER[S^9_ \HYPQ MA5:F<,D4&$SA(I*?^F%D\%A443I1S5@B*TNT9 D-EN@I%HOJ/DML98D7+&%B MMT^L]LDR%X-RVTM28T?=VU*I-4RZ#!,;8=+E9%@WU&/=C">S\F1+GL3@R9[D M>:R;\4#/7H2\Y4+>*2#P3AF#CY=RT#R[EM!>JZ"E6)FK.6CFWWT4+V;/JDOO MSYZ]8D%+R3+7$]HJD8W(IK,0@&PO=V]R:W-H965T&ULC5C9;NLV$/T5 MP^^.N(JD81N(EZ(%6B"X1=MGQ:877,ER)26^_?M2RW7DF9&3/,06?69X#I'KVO1C^R]%S.Q\>JNDRCJ-P>?9:43_G%G\,O^[S(DBH\%H>HO!0^ MV35!61H)QN(H2T[G\6+6M+T4BUG^5J6GLW\I1N5;EB7%?TN?YM?YF(]_-GP[ M'8Y5W1 M9I?DX/_TU5^7ER(\1;_\FE:9PH\_NV2CF]]UH'][S^S M_]*(#V)>D]*O\O2?TZXZSL=V/-KY??*65M_RZZ^^$Z3'HT[][_[=IP%>,PE] M;/.T;/Z/MF]EE6==ED E2WZTGZ=S\WEM?XEM%T8'B"Y W )"WX\"9!<@/P+4 MPP#5!:BO]J"[ UZB%KMS6"NDRI9S(K\.BK:]7!)ZF7'ISI,U[9N;&:G^2V, M9QE:WQ?:SJ+W.D\'6;80T8>X>\@:0_@-$87^;R0$16(I4+BX[V"%$3$#'#Y- MLGF8Y(ZF),=*-O&R'S\@4Y'QJHE7_7BHLX7$#>3<#J1V1@,A!,HJ/J!%DUPT MYB(!EQ:B>[UH)B$5 N2DI)G$)),8,U& 28PZX-X^P@#5W^'NF.CF855AT@FA990&DXF MF37Q@#:R2CYS@;09!ED+O+R$24"SSR!,LP*"0<1XZ2V:.H)E GC: ?4T>6:XWH->2\Y MKL432AX%T\Y"YFL*2 DD8HP8RT,6;&SQ&&HHWB*R#>WI# M@ 1S Z;&:2?@V I,#"<,5_D)CP7<'BL*%^Q>*#AA5#[&'2S[&PIH8ZZ&=ASM M+QP;C($&P[%Y3(S%I>8SV/TADO88@3W& (]9"^PQ$Z'0J8:"J9@I-T"(-B.! MSL=K(?5)\6.TG^";R^9AIGM-M!D)_%)B%=04?T53_+FF^&N:'F6ZUT3; MH\#V:#741#B?%0IM5@*F;5A\ A;]J;J(WU['U.^K^JL)WXOVPJI]J/)+=QD7W6X$%_\#4$L# M!!0 ( %5UDDZ5$""=MP, "P0 8 >&PO=V]R:W-H965T&ULC9C;CN,V#(9?Q?#]K$7*)PV2 ),L%BW0 H,MVEY[$B4QUK92VYEL MW[[R8;..2 UZ,[:5GR(I4Y_%6=U,^ZT[:]T'W^NJZ=;AN>\OSU'4[<^Z+KI/ MYJ(;^\O1M'71V\?V%'675A>'T:BN(A0BC>JB;,+-:AQ[;3I;]WB/AA2>3/FV_#PZV$=BB$B7>E]/TQ1V,N[WNFJ&F:R M?0Z&R_L?LW\9D[?)O!6=WIGJ[_+0G]=A'@8'?2RN5?_5W'[1; M;6='WS=YNHK>AWEFR7:2X$("=T5D)[][0,[#%HDY/CK8444J> ^2S4&.]G*9 M0\;;QZQ]/-K'2_O<68-)DHZ29I3$B8H=U8ZJGF(AA?)DD[#1)#0;Q=NGK'U* MLEGXG[*9),DB3HQEXB1#17$J8D\H&1M*1D,!)Y2,> $!*LV<8*@L3R'VK&O. M!I/38)Q"W#(2R;M0K M%[6/'A2*)/$$BE91.PHQ.Q8GTU#4(?G,+4DLJ\-4L_R?(% M/?KAD0*4*4JY7(V96L D5VX\5(>8YIF'PL!C!1(2$0@7#+/H,:04,I?8K Z5 MR&-/3#RJ("7U:7>_9PH>,4 9 \+=U\!0!DCV.T:6*^';80,C\"7$,\C9'@$[J&'$7DW M"X\99# #+O:0P-SQD)(4, M@'ORG47+<[S]MI'*CA8]5JW;T]B.=L'>7)M^:&<6H_>6]P6''LT9W]I6>&I< M?TXS]=&_%^VI;+K@S?2V QS[M*,QO;91BD_VO9YMZWY_J/2Q'VXS>]]._>OT MT)O+W)M']W\0;/X#4$L#!!0 ( %5UDDY?7?L#L0$ -(# 8 >&PO M=V]R:W-H965T&UL?5-M;YPP#/XK47Y IZJ1- M.K7:]CD'!J(F,4W"T?W[)H%CK$/[0FSCY_%CQ\D&-*^V!7#D74EM<]HZU^T9 MLV4+BMLK[$#[/S4:Q9UW3<-L9X!7$:0D2S>;&Z:XT+3(8NQHB@Q[)X6&HR&V M5XJ;WP>0..0TH9? LVA:%P*LR#K>P NX']W1>(_-+)50H*U 30S4.;U/]H== MR(\)/P4,=F&3T,D)\34X7ZN<;H(@D%"ZP,#]<88'D#(0>1EO$R>=2P;@TKZP M/\;>?2\G;N$!Y2]1N3:G=Y144/->NF<.7 ME+UUJ"86+T7Q]_$4.I[#Q'^!K0/2"9!^ K"Q4%3^A3M>9 8'8L;9=SQ<<;)/ M_6S*$(RCB/^\>.NCYR));C)V#D13SF',29?N4Q&VF*D"T\1MLJ3$7L=-7D3GA;U/XYW\ M21^W_3LWC="6G-#YFXWSKQ$=>"F;*[]"K7]@LR.A=L&\];89UVQT'';3"V+S M,RX^ %!+ P04 " !5=9).WM@6\+0! #2 P & 'AL+W=O&,"* MC:EMEO3O.S:$HA;EQ?:,SSES\3B?C'UV'8 G+UKUKJ"=]\.1,5=UH(6[,0/T M>-,8JX5'T[;,#19$'4E:,9XD[Y@6LJ=E'GUG6^9F]$KV<+;$C5H+^_L$RDP% M3>FKXU&VG0\.5N:#:.$[^!_#V:+%5I5::NB=-#VQT!3T/CV>LH"/@"<)D]N< M2:CD8LQS,+[4!4U"0J"@\D%!X':%!U J"&$:OQ9-NH8,Q.WY5?U3K!UKN0@' M#T;]E+7O"GI'20V-&)5_---G6.JYI60I_BM<02$\9((Q*J-<7$DU.F_THH*I M:/$R[[*/^S3?9(>%MD_@"X&OA+L8A\V!8N8?A1=E;LU$[-S[080G3H\<>U,% M9VQ%O,/D'7JO99I^R-DU""V8TXSA6\R*8*B^AN![(4[\/SK?IQ]V,SQ$^F$; MG2?[ MFN0!8%LC=+W,'P?XMDFYYJL&V<)D=6#O>7R3O_!YVK\) MV\K>D8OQ^+*Q_XTQ'C"5Y 9'J,,/MAH*&A^.[_%LYS&;#6^&Y0>Q]1N7?P!0 M2P,$% @ 57623D:Z?G&S 0 T@, !@ !X;"]W;W)KW<NC@Q59)QKX"OY;=[+!8C-+)348)]$0"W5.[[:'XS[&IX#O$@:W.)-8R1GQ M)1J/54XW41 H*'UD$&&[P#TH%8F"C->)D\XI(W!Y?F?_E&H/M9R%@WM4S[+R M;4YO*:F@%KWR3S@\P%3/-253\9_A BJ$1R4A1XG*I964O?.H)Y8@18NW<9$NP7?_4/@;P7Z5 M8)\(]O\M<2UF]T<2MNBI!MND:7*DQ-ZD25YXYX&]X^E-?H6/T_Y%V$8:1\[H MP\NF_M>('H*4S548H39\L-E04/MX_!#.=ARST?#833^(S=^X^ E02P,$% M @ 57623F::*=%JFJ?1=S)YBKV3K8:3(;972IA?1Y X9'1+/QQ/;=VXX&!Y MVHD:?H![[D[&6VQF*5L%VK:HB8$JHW?;PS$)\3'@I87!+LXD5')&? O&MS*C MFR ()!0N, B_7> >I Q$7L;/B9/.*0-P>?Y@_Q)K][6!TL:5%+UUJ"86+T6)]W%O==R'\6:_ MFV#K #X!^ RXC7G8F"@J?Q!.Y*G!@9BQ]YT(3[P]<-^;(CAC*^*=%V^]]Y)O M>9*R2R":8HYC#%_&S!',L\\I^%J*(_\'SM?ANU6%NPC?_:%POTZ0K!(DD2#Y M;XEK,==_)6&+GBHP=9PF2PKL=9SDA7<>V#L>W^0S?)SV[\+4K;;DC,Z_;.Q_ MA>C 2]E<^1%J_ >;#0F5"\<;?S;CF(V&PV[Z06S^QOEO4$L#!!0 ( %5U MDDXB+81 M $ -(# 9 >&PO=V]R:W-H965T=&JM1EMG.L.C-FB 2WL%7;0^IL*C1;.FZ9FMC,@R@C2 MBO'-YIII(5N:I]%W,GF*O5.RA9,AMM=:F#]'4#AD=$M?'0^R;EQPL#SM1 T_ MP?WJ3L9;;&8II8;62FR)@2JCM]O#<1?B8\"CA,$NSB14QN^)D\XI W!Y?F6_C[7[6L["PAVJ)UFZ)J-[2DJH1*_< M PY?8:KG$R53\=_A LJ'!R4^1X'*QI44O76H)Q8O18N7<9=MW(?Q)DDFV#J M3P ^ _8Q#QL31>5?A!-Y:G @9NQ])\(3;P_<]Z8(SMB*>.?%6^^]Y%M^D[)+ M()IBCF,,7\;,$2,SK]L['^%Z,!+ MV5SY$6K\!YL-!94+QQM_-N.8C8;#;OI!;/[&^5]02P,$% @ 57623D^< M'UZS 0 T@, !D !X;"]W;W)K&UL?5-A;]P@ M#/TKB!]0)"TS*/OK,I[XVD?XF/ -P&C79U)J.2"^!R,Q[J@21 $$BH7&+C? MKG /4@8B+^-EYJ1+R@!Y7=1NZZ@!TIJ:/@@W1..#S#7 M\XZ2N?A/< 7IPX,2GZ-":>-*JL$Z5#.+EZ+XZ[0+'?=QNLD.,VP;D,Z = $< M8AXV)8K*/W#'R]S@2,S4^YZ')]X=4]^;*CAC*^*=%V^]]UKNLB1GUT TQYRF MF'0=LT0PS[ZD2+=2G-*_X.DV/-M4F$5X]IO"?^3?;Q+L(\'^OR5NQ?RIDJUZ MJL"T<9HLJ7#0<9)7WF5@[]+X)K_"IVG_S$TKM"47=/YE8_\;1 =>2G+C1ZCS M'VPQ)#0N'-_[LYG&;#(<]O,/8LLW+G\"4$L#!!0 ( %5UDD[]L0< LP$ M -(# 9 >&PO=V]R:W-H965TOWW'="SMO7N"S##O#=OAB&?C'UT M'8 G3UKUKJ"=]\.1,5=UH(6[,0/T>-,8JX5'T[;,#19$'4%:,7XXO&5:R)Z6 M>?2=;9F;T2O9P]D2-VHM[*\3*#,5-*'/C@?9=CXX6)D/HH6OX+\-9XL66UEJ MJ:%WTO3$0E/0N^1XRD)\#/@N87*;,PF57(QY#,:GNJ"'( @45#XP"-RN< ]* M!2*4\7/AI&O* -R>G]D_Q-JQEHMP<&_4#UG[KJ"WE-30B%'Y!S-]A*6>-Y0L MQ7^&*R@,#THP1V64BRNI1N>-7EA0BA9/\R[[N$_S#4\6V#Z +P"^ FYC'C8G MBLK?"R_*W)J)V+GW@PA/G!PY]J8*SMB*>(?B'7JO99*F.;L&HB7F-,?P;:%EGTG4R1 M8>^DT' RQ/9*:TJFXK_"!:0/ M#TI\CA*EC2LI>^M032Q>BN+OXRYTW(?Q)MU/L'5 ,@&2&;"/>=B8*"I_X(X7 MF<&!F+'W'0]/O#TDOC=E<,96Q#LOWGKOI=BFUQF[!*(IYCC&),N8.8)Y]CE% MLI;BF/P#3];AZ:K"-,+3/Q3>K!/L5@EVD6#WWQ+78F[_2L(6/55@FCA-EI38 MZSC)"^\\L'=)?)/?X>.T?^.F$=J2,SK_LK'_-:(#+V5SY4>H]1]L-B34+AQO M_=F,8S8:#KOI!['Y&QK8>LP$ -(# 9 M>&PO=V]R:W-H965T29M<--I(Y;YJ6V-X JR-("D(WFX]$,JYPF4??R92Y'IS@ M"DX&V4%*9IZ/(/18X"U^<=SQMG/!0K/QEOD9FEYA*4Y5HA TV! MK[>'XR[$QX![#J-=G%&HY*SU8S"^UP7>!$$@H'*!@?GM C<@1"#R,GXG3CRG M#,#E^87]:ZS=UW)F%FZT>."UZPJ\QZB&A@W"W>GQ&Z1Z/F"4BO\!%Q ^/"CQ M.2HM;%Q1-5BG96+Q4B1[FG:NXCZFFRS!U@$T >@,V,<\9$H4E7]ACI6YT2,R M4^][%IYX>Z"^-U5PQE;$.R_>>N^EW&;[G%P"48HY3C%T&3-'$,\^IZ!K*8[T M#9RNP[-5A5F$9^\H_(M@MTJPBP2[_Y:X%O/YGR1DT5,)IHW39%&E!Q4G>>&= M!_::QC=Y#9^F_9:9EBN+SMKYEXW];[1VX*5LKOP(=?Z#S8: QH7C)W\VTYA- MAM-]^D%D_L;E'U!+ P04 " !5=9)..T7P,;O^=F8?$3S:#L 1YZ5U+:@G7/]@3%; M=:"XO<(>M+]IT"CNO&E:9GL#O(X@)5F:)!^9XD+3,H^^DRES')P4&DZ&V$$I M;EZ.('$LZ(Z^.AY$V[G@8&7>\Q:^@_O1GXRWV,)2"P7:"M3$0%/0F]WAF(7X M&/!3P&A79Q(J.2,^!N.N+F@2!(&$R@4&[K<+W(*4@)HYZ9(R -?G5_8O ML79?RYE;N$7Y2]2N*^@U)34T?)#N <>O,-?S@9*Y^&]P >G#@Q*?HT)IXTJJ MP3I4,XN7HOCSM L=]W&ZR?8S;!N0SH!T 5S'/&Q*%)5_YHZ7N<&1F*GW/0]/ MO#NDOC=5<,96Q#LOWGKOI=QE2?4F1;J4XIO_!TVWX M?E/A/L+W?RE\(W^V29!%@NS=$K=B_E7)5CU58-HX3994..@XR2OO,K W:7R3 M/^'3M-]STPIMR1F=?]G8_P;1@9>27/D1ZOP'6PP)C0O'3_YLIC&;#(?]_(/8 M\HW+WU!+ P04 " !5=9).)07#'+,! #2 P &0 'AL+W=OT7P,;O^=F8;$3S:%L 1YZUZFQ.6^?Z V.V;$$+>X4] M=/ZF1J.%\Z9IF.T-B"J"M&)\M_O(M) =+;+H.YDBP\$IV<')$#MH+@5"#R,IYF3KJD#,#U^97]2ZS=UW(6 M%FY1_9*5:W-Z34D%M1B4>\#Q*\SU?*!D+OX;7$#Y\*#$YRA1V;B2O/7>2Y&D^XQ= M$<?4G!MU(<^7]PO@W?;RK<1_C^ M#85_$:2;!&DD2-\M<2LF_2<)6_54@VGB-%E2XM#%25YYEX&]X?%-_H1/TWXO M3",[2\[H_,O&_M>(#KR4W94?H=9_L,504+MP_.3/9AJSR7#8SS^(+=^X^ U0 M2P,$% @ 57623LI38"2T 0 T@, !D !X;"]W;W)K&UL?5-A;]L@$/TKB!]0$N*V461;:EI5G;1)4:MMGXE]ME'!N(#C M[M_WP*[G;=:^ '?<>_?N.-+!V%?7 'CRKE7K,MIXWQT8)9UXX.#Y6DG:G@!_[T[6;38S%)*#:V3IB46JHS>;0_'),3'@!\2!KF;C.XI*:$2O?+/9GB"J9YK2J;BO\(%%(8')9BC,,K%E12]\T9/+"A%B_=Q MEVW3_P/DZ?+>JX,]:'_3H%'<>=.T MS/8&>!U!2K(T2=XQQ86F91Y]9U/F.#@I-)P-L8-2W/P^@<2QH#OZXG@4;>>" M@Y5YSUOX!NY[?S;>8@M++11H*U 3 TU![W?'4Q;B8\ / :-=G4FHY(+X%(S/ M=4&3( @D5"XP<+]=X0&D#$1>QJ^9DRXI W!]?F'_&&OWM5RXA0>4/T7MNH(> M**FAX8-TCSA^@KF>6TKFXK_ %:0/#TI\C@JEC2NI!NM0S2Q>BN+/TRYTW,?I M9G\WP[8!Z0Q(%\ AYF%3HJC\ W>\S V.Q$R][WEXXMTQ];VI@C.V(MYY\=9[ MK^4N.^3L&HCFF-,4DZYCE@CFV9<4Z5:*4_H&GF[#]YL*]Q&^_T?AW39!MDF0 M18+LOR5NQ-PFKY*P54\5F#9.DR45#CI.\LJ[#.Q]&M_D;_@T[5^Y:86VY(+. MOVSL?X/HP$M);OP(=?Z#+8:$QH7C>W\VTYA-AL-^_D%L^<;E'U!+ P04 M" !5=9).ZLFGE+0! #2 P &0 'AL+W=O,ZW;1IM+2=+I\O-S?.PX^6C=D^\ GG6ROB"=B'T1\9\U8$6_L;V8/"FL4Z+@*9KF>\= MB#J!M&)\MWO%M)"&EGGRG5V9VR$H:>#LB!^T%N['"90="YK1%\>C;+L0':S, M>]'"9PA?^K-#BRTLM=1@O+2&.&@*>I\=3X<8GP*^2AC]ZDQB)1=KGZ+QH2[H M+@H"!56(# *W*SR 4I$(97R?.>F2,@+7YQ?V=ZEVK.4B/#Q8]4W6H2OH'24U M-&)0X=&.[V&NYY:2N?B/< 6%X5$)YJBL\FDEU>"#U3,+2M'B>=JE2?LXW? W M,VP;P&< 7P!W*0^;$B7E;T409>[L2-S4^U[$)\Z.''M316=J1;I#\1Z]US*[ MS7)VC41SS&F*X>N8)8(A^Y*";Z4X\;_@?!N^WU2X3_#];PK_07#8)#@D@L-_ M2]R*V?^1A*UZJL&U:9H\J>Q@TB2OO,O WO/T)K_"IVG_)%PKC2<7&_!E4_\; M:P.@E-T-CE"''VPQ%#0A'E_CV4UC-AG!]O,/8LLW+G\"4$L#!!0 ( %5U MDDY!UC>M=@( '() 9 >&PO=V]R:W-H965T'QOP MN>=<\+E <97J59\X-]%;+1J]C$_&M(^$Z/+$:Z8?9,L;^^4@5']A9F&=Y_<+["M9%USV)3 MJ=E;]ZX:_[YV7V;3/@P'I'U .@3D7H=T0C[S3\RP5:'D-5+=XK?,_6/ZF-JU M*=V@7PK_S2:O[>AE16?3@EP<48_9=)CT%C,@B&4?)%(DL4GOPE,QV5\MSXF\;-Z'"A6*?^R/P'[VXCWYDZ5HV. M=M+8@]Y) _V'Y[L!6CH"'XPKIG9MNIN 5W'R+:_X9#AFK7Z"U!+ M P04 " !5=9).@Y!!N_(! "3!0 &0 'AL+W=OI%8@:SK !2K60LO'':OIS2DV\G+^J?S:UJUKV M1,"&T=]M)9O"SWRO@IJP]22^9XO_!F>@"JZ=J!P'1H7Y]PXG(5EG M5925CKQ,8]N;<9QV5IFEN0F1)40S(<1O$F)+B#]*P): /TI(+"&Y(J"I=G.8 MCT22,N=L]/CT' :B7UVX3M1U'?2BN1VSI\Y3J-5S&69QCLY:R&(>)DRTP. E M9G.+B9:(1P?B?@G9NA(E,P:I0N9J(FP4P Z![.IN\*W/P/S M.EVE3J_HXO'J=O6=\&/;"V_/I/H.S&NM&9.@5(,[)=BH#CD'%&JIIRLUYU.? MF +)!ML"T=R'RW]02P,$% @ 57623C@VE@[J 0 ,P4 !D !X;"]W M;W)K&ULC51A;YLP$/TKR#^@!@-K&@'2FF3:I$V* M.G7[[, EH!K,;"=T_WZV<6D@5K4OL>_\WKM[YN)LX.)%U@ J>&U9)W-4*]6O M,99E#2V5=[R'3I\VY:*OX_ ^)"C"+TEGII3K4P"%UE/3_ 3U'._%SK"DTK5M-#)AG>!@&.. M/D?K76+P%O"K@4%>[0/CY,#YBPF^53D*34/ H%1&@>KE AM@S CI-OXX3325 M-,3K_9OZ%^M=>SE0"1O.?C>5JG.T0D$%1WIFZHD/7\'Y25'@S'^'"S --YWH M&B5GTOX&Y5DJWCH5W4I+7\>UZ>PZC"?WQ-'\!.((9"+HVA\18D>(WPG)AX3$ M$9+_):2.D"X(>/1N+W-+%2TRP8= C./04S-UT3K5GZLT2?MU[)F^3ZFSER)Z M"#-\,4(.\SABR P3S3&;6PR9([8>Q,,I?!VLCDAGC=$"L07PN0T"\0 M>P5B*Y#,.H@7U^'#)/XBB;=(XA%(%T5&3&HQG<6D8406J,TMBJQ(LD!M/:AT MM43M_!43DMZ8PU?#99Z3'U2/5%X>B>+?U!+ P04 " !5=9).(8EGH_ ! !-!0 &0 M 'AL+W=O&BM3&U3=C^?7UA*4V\4GG ]OC,.6<,GFSBXD6V "IX9;27 M>=@J-1P1DF4+C,@'/D"O=VHN&%%Z*1HD!P&DLDF,(AQ%"6*DZ\,BL[&S*#(^ M*MKU OXT<$D5_/ 5'+A_,4L/E=Y&!E#0*%4AH'HX0I/0*DATC9^ MS9SA(FD2U_,W]H^V=EW+A4AXXO1G5ZDV#],PJ* F(U7/?/H$$K"KQ0E9YQ^( M(D4F^!0(=_8#,9]X<\3Z;$H3M$=A][1YJ:/78G-(,G0U1#/FY#!XC5D02+,O M$M@G<<+WZ8>]GV#K];BU!/$_!.F-1X=)+*9WF#2-S.-7BKU*L4?I<*,4WRGA M%+\OM/,*[>Z$\'L$B9<@\1!L;ISZ,-@OLO>*[#T$6S]!ZB5(_\.E#Q/?B*#5 M[\Q -/8BRZ#D8V^;R"JZ](I';*_#7[AK-%^):+I>!A>N]*6ROW[-N0)M)7K0 MGZ75O6U94*B5F>[U7+@;[A:*#W/S0DL'+?X 4$L#!!0 ( %5UDDZNZ^.F M$@( &,& 9 >&PO=V]R:W-H965TFA4XUH@LDG,KP7;391M0:.,3W!@9U,P]L*'LAGNSBT[$,J?4( M.!RTI6!FN,(6.+=,QH^?(VDX:5K#V_D+^P<7O EFSQ1L!?_1''5=AGD8'.'$ M+EP_BN$CC &E83!&_QFNP W<>F(T#H(K]PX.%Z5%.[(85UKV[,>F<^/@3[)\ M-,,-XM$@G@RBY:L&R6B0S R(]\R%^IYI5A52#('TM]4S^U%$F\0D\V W7>[< MF8E6F=UK%=.T(%=+-&(>/":^PV3WF"V&64T88GR8'(E11V)'L+PCR'&"!"5( M$(+US$N/R1RF&D[71EYM*W/;_0HA];.IG^*]5O4$L#!!0 ( %5UDDZ7AKZP MC@, )X0 9 >&PO=V]R:W-H965TSP' MD]E9M&_=@7/I?=15T\W]@Y3'FR#H-@=>%]T7<>2->K(3;5U(==GN@^[8\F+; MD^HJH&&8!'51-OYBUM][;A7/X_/K;H*+E&V917B35^LMW,_U!GQBF^D#E&HPSM?\JK2D50>?TQ0_Z*IB>/SS^@/_>#58%Z+ MCB]%];O1 M&Z*7Z4;?[5=E_U"MHT[=?5]0DL^"=QW)8&X'#!UC:&ACEA"&V)@["$-MS#V$ MB6S, X1A-N81P-B(U121.(-: T&I'84HA[$,@:7/LPH+$44RC$4@EB(03P$!:ZHTHF4C3)4D0)<1$"V(AK MWT\&9"LQ[(5$$"ZW,B!K9A*T-2FV+0!@.T4*-+<%&CNV-U@@2#7A8/1]XS^M/NR MZ;Q7(=7'4?_]LA-"&ULC95OKYL@%,:_BO$#%+6@MK$FNW;-EFQ) PA)2]D+SPD1SFM5UGSGYD(T6P#X.2<5YBO: MD%J^N5)682&[[ 9XPPB^:%%5@L#S0E#AHG;31(\=69K0NRB+FAR9P^]5A=GO M)U+2=N?Z[MO 2Z W\*$C+!VU'57*B]$5U/E]VKJ<,D9*-!,E*6*I"T\)[*9YI^XF8>I#KF.*_D @;F5T0&$'0"WSX3\':"-9+!= (X%(! M,@*T5! :03@1@&ZR].SOL*A AGGJF&#$P#&369@QL;<0FS'R<8[X&W_,'&S,WU1 %MM7'%@K#G0 M. B )CFR#HDT4FO$6WG>A-K_CQIY65N]K.=>)M.6=0@:9-ELO.XW\;.$''F" M5D]P[FFR(3(XRQ3$ 403/Q8*Q0-JY 59O:"YE^G&0XN\6*B1EV[_S2GD^<&$ M.M@I&* -M-<66FL+9[4%Z)W)B:P!(DN $D6 M,#B2U*WU%;-;47/G1(4\W?09=*54$!G06\E8N;PH^TY)KD(U(]EFW771=01M MS$T(^NLX_0-02P,$% @ 57623L.8MO/4 P T!, !D !X;"]W;W)K M&ULE5C;CILZ%/T5Q <,^ 9DE$1JDU:MU$JC5N?T MF4F<"2K@%#R3]N_+Q8W 7I[2EW#)VC=[KV7C]54UW]NSE#KX695UNPG/6E_N MHZ@]G&65MW?J(NONGY-JJEQWC\U3U%X:F1\'HZJ,:!PG4947=;A=#^\>FNU: M/>NRJ.5#$[3/594WO][*4ETW(0G_O/A2/)UU_R+:KB_YD_PJ]7^7AZ9[BFY> MCD4EZ[90==#(TR9\0^[?\<%@0/Q?R&L[N0_Z4AZ5^MX_?#QNPKC/2);RH'L7 M>7=YD3M9EKVG+H\?QFEXB]D;3N__>'\_%-\5\YBW9]+%.*BR'7Z#PW.K566\=*E4^<_Q6M3#]3K^ MDS!CA@VH,: W QJ_:L", 5MJP(T!OQF(]%4#80R$%2$::Q\&A?SG,SO!?-YYM]_9E2T6VCEYZ1P;S=L30&68UQ^P )HGG MF#W"D#GF'<+0&R;J:KD51&%!='# 9PZ8E-NGG$@U%!Y2NVD,-']L3#9"6![RCPN,-T)XKNP5XW$39=[<\5\)X#P(K4#I?\2 M"+.>($I[E)I@3A.7U'9?[0QF\112S'X*V.^TBP$MCX7I3UWZ\Y7'@V=%1L2V MMW6-82=@")=DQ5TFLWAD3@KA9+\Y3PH+#P'XC MM3EL0--0OHTY%B6&-A+V;@.!,E\UGB\ H$@9L>.XBI0*?VLQ+$L,*$YFKPH& ME"QM8X:EB:%/!OLSB[F:\UI56'(8D)S,B01 /K%E6&_8DJT&^Y>M!L.JQ,!6 M(_-L-1@6$89$Q%Y1#6CIBLJQ0'#TH6&ST8 6K*@<?-4U&WPJ+16U7#2<5)*R\YA?-?-XUGFQ]M#*4^ZOTV[^V8\8QH?M+J8 M\[/H=HBW_0U02P,$% @ 57623KK0*+E&!0 NAP !D !X;"]W;W)K M&ULE5G;;N,V$/T5PQ\0D1Q2EX5CH+DUNYL P19M MGY68B8V5+5=2DNW?5Y(5Q^+,2=P7VY+/7"C..1Q2L]>R^EDOO6\FO];%ICZ= M+IMF^R6*ZH>E7^?U2;GUF_:?Q[):YTU[63U%];;R^:(W6A>142J.UOEJ,YW/ M^GMWU7Q6/C?%:N/OJDG]O%[GU;]GOBA?3Z=Z^G;CQ^IIV70WHOELFS_Y/WSS MY_:N:J^BO9?%:NTW]:K<3"K_>#K]37^Y=:XSZ!%_K?QK??![T@WEOBQ_=A=? M%Z=3U67D"__0="[R]NO%G_NBZ#RU>?PS.)WN8W:&A[_?O%_U@V\'*Z; MQ@YEL8 8#LSJW MZ=9'S[=^FW#]/N.ZKZEH5XM]<5_D33Z?5>7KI-KQ(PYES#)&',A8=(QYE+"9&/,%:[A*$QYD;"V#'F5L*\SU?43O9^QHT\XZ;W M8 ^?G@IF_(IC#I(=!2$Y"#$'%,[B#N)ZR&8W$DLN"2=@!XL/8)0E3ALY'2NG M8_EX@F*XLBQ.ETY051QD8V4S.1:4UT[A,0'2:\YZ4C8<^P1W_;F_<>Y <327'%*LB4A8K%BG*= ,#:1)<]TAE8:A)! * M!-1)"_*D51A( H%J-D###-[; $M&**501D# C"!@ M.N2Q"+(@$.IH! G3+@PD@<"Z:X R&4&9=%B@(@@LG 9(D^'21#I@C3HCH;^)$P?67D*;GL]W/3?$]S.F750([&<(" 0) D$!G2X'T*A' M(MR/$= ($NA/%,9RS,Q7'FIK"_=^BPD?-6V_ X0 "1 M#=?3Z."50O=6[S:OGE:;>G)?-DVY[E\A/)9EXUN'ZJ1UN/3Y8G]1^,>F^YFT MOZO=V[3=15-NAS>%T?YUY?P_4$L#!!0 ( %5UDDZ.$^U$\ , *,4 9 M >&PO=V]R:W-H965T#FP7[.#@_&B#/^;+A/:>L+KQY;T^, M=>&Y8?!J"H][/O4 MJ_*B=C>KX=ISLUGQCZXL:O;<..U'5>7-?UM6\LO:1>[7A9?B[=2)"]YF=<[? MV%^L^_O\W/1GWM7+H:A8W1:\=AIV7+O?T/T3&0P&XI^"7=K)L2-*>>7\79Q\ M/ZQ=7V3$2K;OA(N\__ID.U:6PE.?Q[_2J7N-*0RGQU_>'X;B^V)>\Y;M>/FS M.'2GM1N[SH$=\X^R>^&71R8+"EU'5O\G^V1ECXM,^AA[7K;#7V?_T7:\DE[Z M5*K\U_A=U,/W9?R%?IG!!E@:X*L!"FX:$&E ; T":1#8&H32(+0UH-* VAI$ MTB"R-8BE0?R_ ;EID$B#Q#8"\K]VSE=,O''+AWLHS;M\LVKXQ6G&Q^"&N''[L[Z.VO_JY(0%=>9_"DV2V(X,G#$[".;.S8%(+)K-@'G2& M!-&<^0-BXCGS"#')G/D.Y#,GGJ",KXC7K_YU"S"\!7AP$$P$MA# GA0)&.7:*F&OO@H3ZF.H3DVRT?L)*AA/I!1I J4KZ>$]8P #,7F MC$RJBH",8C4C"#)(!S)H!]+%@U!?#01 V" +R* +2!<&G%"##X,R(/VQQZHT M;"$HT3;3 DIMH&P!FM=ET"($B%%B>"J106B0KC3 V@!0DJAK8P&E-E"V ,WK M,N@: H2-FNX]@V0A0+,H5MUU;'"DOML&P1F]=G$%0$*"HE:GV)UF:0 M6MLBDBXCV4UD/L\8]!@#>DR59K:5T#2,LJ6[921=1K*;R+P>@YIC7:BU1U,R M"R/:S@Y+[;!L$9N79YH_@?:@UP=!IG4T]! ,]!!U:-M*R#BUR76TH5(K*ENB MYK49>AN&1EKU'RD)38<+>F/>P89^@_5^0TBHQ@JU6%B?P'9V6&J'98O8O#Y# M+\3 U$T-,RHV]!T,]1VJ5A5ITD"'CV$ P(8&A:$&I8XC$IH',P4R= H,=0K# MI$$,ZDP@=596)B.Z:")";OQ;0PS:28 A5UV:3$)J-"62-WFI(5[?_=;P:7F(<.>]8[]&_ZWV=6'ZXGI3LV(G#J#]NQM=FXTG'S_*5H'=]+[GY M#5!+ P04 " !5=9).\4E]Q:\$ !$& &0 'AL+W=OPGI?Z6S=&15YR!F+PB+;[H+YM'NVJN;3\KW) MMSN]JB;U>U%DU3\+G9>'60!!_^#']FW3M _"^72?O>G?=?/'?E69N_#D9;TM M]*[>EKM)I5]GP6]P]21Y:] A_MSJ0WUV/6F'\ER6/]N;V_4L8&U&.MLB M,Q\?>JGSO/5D\OC;.@U.,5O#\^O>^TTW>#.8YZS6RS+_:[MN-K,@"29K_9J] MY\V/\O!5VP&I8&)'?Z\_=&[@;28FQDN9U]W_R^[#"Z[M 7 M'MS*AT=>=42]SIIL/JW*PZ0Z:LT^:R4-KHR5<=X^[:C??6G(6ING'W,1I=/P MH_5D,8LCAI]C8C;$+#$,##'7&(8/,9\QC!AB;C",'&*^8!@UQ'S%,-$0>9"#(3M1'H\8U6%VQV03+IUB?D=0*G%1*Q^E&' ']82C)%>I MQ$O^\$@*CZ202.[".F*B\SF^%"G"(T5> M)$ABW$.,>XB17)T:?HO]]7 IUP2/E'B1N%*XAQ3WD"*Y.B+SD/JY2BK1MJVB M0LZ00,2T M4,8$2R%D1F:S7(1TEZ3(0Z "8/">&#X"!@)/0ZG/"R!04<(B(6 MP5880=D

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end

U,XG9YO!8<5^ M%0JX=4F&%.K78CEJI.*WRFM BHV7<-W%]+[UBOK> D!]*;>T>9]/TO,)4LZ# MMGO@#I[8WC)-RWXM%J"GD+]L=).>)@(:FU3"I&UM$AS$\$EO$B[@(3#I7Y(9 M_>L2!A/INPL@GB))A'^9Q>/OG\5T)))'V\B"@HFKJ3!V0/_D S _9F$P#C*& MU?$#>)(E7+FTMRA8"7S_-/126#TM[>1'D+[Z53_2O/H_OZF=R 3R33V43^FR M[/%@M_'@D>C!Z8O&@]K5OTAZL,>#'<.#[=�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